Programmed cell death protein 1 antibodies
By developing antibodies that specifically bind to PD-1 and their antigen-binding fragments, immune cell signaling is activated, solving the problem that existing PD-1 antibodies cannot effectively activate immune cells in cancer immunotherapy and improving the efficacy of cancer treatment.
Patent Information
- Application Number
- CN202411092492.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-04-13
- Filing Date
- 2018-09-07
- Publication Date
- 2024-11-08
AI Technical Summary
Existing PD-1 antibodies are unable to effectively activate immune cells in cancer immunotherapy, resulting in some patients not responding to immunotherapy and a lack of effective predictive biomarkers.
Antibodies and their antigen-binding fragments that specifically bind to PD-1 and activate immune cell signaling have been developed, including CDR sequences of the heavy and light chains, which can bind to PD-1 and promote the activation signaling of immune cells, especially CD8+ T cells.
It enhances the adaptive immune response of the immune system, activates CD8+ T cells, and improves the therapeutic effect on cancer.
Smart Images

Figure BDA0004986968570000271 
Figure BDA0004986968570000281 
Figure BDA0004986968570000291
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application is a divisional application of the Chinese invention patent application with application number 201880058085.5, application date September 7, 2018, and invention name “Programmed cell death protein 1 antibody”. The original application is a national phase application with international application number PCT / US2018 / 049854, which claims the rights and priority of U.S. provisional patent application 62 / 555,156 filed on September 7, 2017, U.S. provisional patent application 62 / 624,843 filed on February 1, 2018, and U.S. provisional patent application 62 / 657,323 filed on April 13, 2018, the contents of which are hereby incorporated by reference in their entirety. Technical Field
[0003] The present invention generally relates to immunomodulatory and PD-1 specific antibodies and methods of use thereof. Background Art
[0004] The programmed cell death receptor protein (PD-1) / programmed cell death receptor protein ligand 1 (PD-L1) pathway has shown promising clinical success as a target for cancer immunotherapy. Antibodies currently targeting PD-1 or PD-L1 can block this interaction and enhance the immune response against cancer cells. Successful clinical trials of PD-1 monoclonal antibodies and other immune checkpoint inhibitors have opened up new avenues for cancer immunology. However, most cancer patients do not respond to new immunotherapies, leading to increasingly in-depth research on combination therapies and predictive biomarkers (Iwai, Y. et al., Journal of Biomedical Science, Vol. 24, p. 26 (2017)).
[0005] It is therefore an object of the present invention to provide compositions and methods for modulating PD-1 signaling.
[0006] Another object of the present invention is to provide antibodies and antigen-binding fragments thereof that specifically bind to PD-1 and regulate PD-1 signaling.
[0007] Another object of the present invention is to provide compositions and methods for treating cancer.
[0008] Another object of the present invention is to provide compositions and methods for treating infections. Summary of the invention
[0009] Provided are antibodies and antigen-binding fragments thereof that specifically bind to PD-1, preferably human or mouse PD-1, and induce or promote an immune response that activates immune cell proliferation or activity. In one embodiment, the disclosed antibodies and antigen-binding fragments thereof specifically bind to PD-1 expressed on immune cells. The binding of the disclosed antibodies and antigen-binding fragments thereof to PD-1 on immune cells causes activation signals (e.g., signals that enhance or promote cytokine production and / or immune cell proliferation activation) to be delivered to immune cells. Immune cells expressing PD-1 include, but are not limited to, B cells and T cells and myeloid cells (Riley, J., Immunol Rev., Vol. 229, No. 1, pp. 114–125 (2009)). In one embodiment, the immune cell is a T cell, preferably a CD8+T cell.
[0010] Another embodiment provides a method of stimulating, promoting or enhancing an adaptive immune response in a subject in need thereof, by administering to the subject an effective amount of the disclosed anti-PD-1 antibody or antigen-binding fragment thereof to induce, enhance or promote an adaptive immune response in the subject.
[0011] One embodiment provides an antibody or antigen-binding fragment thereof having a heavy chain complementarity determining region (CDR) having an amino acid sequence according to SEQ ID NOs: 6, 7 and 8 and a light chain CDR having an amino acid sequence according to SEQ ID NOs: 12, 13 and 14, wherein the antibody or antigen-binding fragment thereof immunospecifically binds to PD-1.
[0012] One embodiment provides an antibody or antigen-binding fragment thereof having a heavy chain that has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO:4 or 5.
[0013] One embodiment provides an antibody or antigen-binding fragment thereof having a light chain that has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO: 10 or 11.
[0014] One embodiment provides an antibody or any antigen-binding fragment thereof having a heavy chain and a light chain, wherein the heavy chain has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO:4 or 5, and the light chain has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO:10 or 11.
[0015] One embodiment provides a transgenic animal engineered to express any of the disclosed antibodies or antigen-binding fragments thereof. In one embodiment, the animal is a mouse.
[0016] One embodiment provides a nucleic acid encoding a heavy chain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO:4 or 5.
[0017] One embodiment provides a nucleic acid encoding a light chain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO:10 or 11.
[0018] One embodiment provides an antibody or antigen-binding fragment thereof having a heavy chain CDR having an amino acid sequence according to SEQ ID NOs: 18, 19 and 20 and a light chain CDR having an amino acid sequence according to SEQ ID NOs: 24, 13 and 25.
[0019] One embodiment provides an antibody or antigen-binding fragment thereof having a heavy chain that has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO:16 or 17.
[0020] One embodiment provides an antibody or antigen-binding fragment thereof having a light chain that has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO:22 or 23.
[0021] One embodiment provides an antibody or antigen-binding fragment thereof having a heavy chain and a light chain, wherein the heavy chain has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO: 16 or 17, and the light chain has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO: 22 or 23.
[0022] One embodiment provides a nucleic acid encoding a heavy chain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO:16 or 17.
[0023] One embodiment provides a nucleic acid encoding a light chain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO:22 or 23.
[0024] One embodiment provides an antibody or antigen-binding fragment thereof having a heavy chain CDR having an amino acid sequence according to SEQ ID NOs: 29, 30 and 31 and a light chain CDR having an amino acid sequence according to SEQ ID NOs: 35, 36 and 37.
[0025] One embodiment provides an antibody or antigen-binding fragment thereof having a heavy chain that has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO:27 or 28.
[0026] One embodiment provides an antibody or antigen-binding fragment thereof having a light chain that has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO:33 or 34.
[0027] One embodiment provides an antibody or antigen-binding fragment thereof having a heavy chain and a light chain, wherein the heavy chain has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO:27 or 28, and the light chain has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO:33 or 34.
[0028] One embodiment provides a nucleic acid encoding a heavy chain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO:27 or 28.
[0029] One embodiment provides a nucleic acid encoding a light chain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO:33 or 34.
[0030] One embodiment provides an antibody or antigen-binding fragment thereof comprising three light chain CDRs having an amino acid sequence selected from the group consisting of SEQ ID NO: 12, 13, 14, 24, 25, 35, 36 or 37.
[0031] Another embodiment provides an antibody or antigen-binding fragment thereof comprising three heavy chain CDRs having an amino acid sequence selected from the group consisting of SEQ ID NO: 6, 7, 8, 18, 19, 20, 29, 30 or 31.
[0032] Another embodiment provides an antibody or an antigen-binding fragment thereof comprising three light chain CDRs and three heavy chain CDRs, wherein the three light chain CDRs have an amino acid sequence selected from the group consisting of SEQ ID NO: 12, 13, 14, 24, 25, 35, 36 or 37, and the three heavy chain CDRs have an amino acid sequence selected from the group consisting of SEQ ID NO: 6, 7, 8, 18, 19, 20, 29, 30 or 31.
[0033] One embodiment provides an antibody or epitope-binding fragment or fusion protein thereof that immunospecifically binds to SEQ ID NO: 38. In one embodiment, the antibody binds to SEQ ID NO: 38 on PD-1. In one embodiment, the antibody binds to PD-1 expressed on the surface of an immune cell and induces or promotes a signal that activates or stimulates the immune cell through PD-1. In one embodiment, the activated or stimulated immune cell is a T cell, such as a CD8 + T cells.
[0034] In some embodiments, the antibody or antigen-binding fragment thereof is human, mouse, chimeric, humanized, monoclonal, bispecific, trispecific, or multispecific.
[0035] One embodiment provides a pharmaceutical composition comprising one or more of the disclosed antibodies or antigen-binding fragments thereof. In some embodiments, the pharmaceutical composition comprises a second therapeutic agent and / or a pharmaceutically acceptable excipient. An exemplary second therapeutic agent comprises cyclophosphamide.
[0036] One embodiment provides a method of inducing, promoting or enhancing an immune response in a subject in need thereof by administering to the subject an effective amount of one or more of the disclosed antibodies or antigen-binding fragments thereof to induce, promote or enhance an immune response in the subject.
[0037] One embodiment provides a method for treating cancer in a subject in need thereof by administering to the subject an effective amount of one or more of the disclosed antibodies or antigen-binding fragments thereof to treat the cancer in the subject.
[0038] One embodiment provides a method for reducing tumor burden in a subject in need thereof by administering to the subject an effective amount of one or more of the disclosed antibodies or antigen-binding fragments thereof to reduce tumor burden in the subject.
[0039] One embodiment provides a method for treating an infection in a subject in need thereof by administering to the subject an effective amount of one or more of the disclosed antibodies or antigen-binding fragments thereof to treat the infection in the subject. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 4G9 and human PD-1 over time. The graph shows the traces of human PD-1 at concentrations of 0 nM, 125 nM, 250 nM, 500 nM, 500 nM and 1000 nM.
[0041] Figure 2 is a graph showing the interaction kinetics between monoclonal antibody 4G9 and mouse PD-1 over time. The graph shows traces of mouse PD-1 at concentrations of 0 nM, 62.5 nM, 125 nM, 500 nM, 500 nM, and 1000 nM.
[0042] Figure 3 4C12 and human PD-1 over time. The graph shows the traces of human PD-1 at concentrations of 0 nM, 125 nM, 250 nM, 500 nM, 500 nM and 1000 nM.
[0043] Figure 4 is a graph showing the interaction kinetics between monoclonal antibody 5C2 and human PD-1 over time. The graph shows traces of mouse PD-1 at concentrations of 0 nM and 1000 nM.
[0044] Figure 5 is a graph showing the interaction kinetics between monoclonal antibody 5C2 and mouse PD-1 over time. The graph shows traces of human PD-1 at concentrations of 0 nM, 62.5 nM, 125 nM, 250 nM, 500 nM, 500 nM, and 1000 nM.
[0045] Fig. 6A are flow cytometry histograms of EL4 cells stained with an isotype control antibody or the commercial anti-PD-1 antibody J43. Figure 6B are flow cytometry histograms of EL4 cells stained with secondary antibody alone or with antibodies 4G9, 5C2, and 4C12. Figure 6C are flow cytometry histograms of EL4 cells stained with secondary antibody alone or with antibody 4G9. Fig.6D are flow cytometry histograms of EL4 cells stained with secondary antibody alone or with antibody 5C2. Fig. 6Eare flow cytometry histograms of EL4 cells stained with secondary antibody alone or with antibody 4C12. Fig. 6F is a bar graph showing the binding of various purified mouse PD-1 antibodies to EL4 cells.
[0046] Fig. 7A and Figure 7B Figure 2 shows the expression of IFNγ in supernatants from CD4 T cells treated with various antibodies. Fig. 7A ) or IL-2 concentration. The X-axis is the treatment group and the Y-axis is the concentration (ng / ml). Figure 7C is a bar graph showing the concentration of IFNγ in supernatants from human CD4 T cells treated with 4G9 or 5C2 antibodies. The X-axis represents the treatment group and the Y-axis represents the concentration (ng / mL).
[0047] Figure 8 is a bar graph showing the intracellular staining level of pAKT in mouse CD4 T cells treated with various antibodies. The X-axis represents the treatment group, and the Y-axis represents pAKT (S473) MFI.
[0048] Fig. 9 is a Western blot showing the IgG heavy and light chains in various antibodies.
[0049] Fig.10 is a bar graph showing the binding of 4G9 and 5C2 antibodies to human PD-1-Fc. The X-axis represents antibody concentration, and the Y-axis represents OD450.
[0050] Fig.11A and Fig. 11B Figure 4 shows the interaction of 4G9 and 5C2 antibodies with PD-1KO mice ( Fig.11A ) or PD-1WT mice ( Fig. 11B ) flow cytometry histogram of PD-1 binding in CD4 T cells.
[0051] Fig.12 is a line graph showing the expression of pS6 in CD4 T cells treated with 4G9, 5C2, commercial Ab-1, commercial Ab-2 or not. The X-axis represents the concentration of total protein (μg / ml), and the Y-axis represents OD450.
[0052] Fig.13A is a schematic diagram showing the experimental design used for the TC-1 tumor experiments. Fig. 13B Figure 2 shows the average tumor volume (cm) of TC-1 tumor-bearing mice treated with E7 Vax, 4G9, RMP 1-14, E7 Vax+RMP 1-14, E7 Vax+4G9 or not. 3) over time (days). The X-axis represents time (days) and the Y-axis represents the average tumor volume (cm 3 ). Fig. 13C is a line graph showing the percentage survival over time of TC-1 tumor-bearing mice treated with E7 Vax, 4G9, RMP 1-14, E7 Vax+RMP 1-14, E7 Vax+4G9, or not treated. Fig.13D Figure 2 shows the average tumor volume (cm2) of TC-1 tumor-bearing mice treated with or without E7 Vax, 4C12, 5C2, RMP 1-14, E7 Vax+RMP 1-14, E7 Vax+4C12, E7 Vax+5C2. 3 ) over time (days).
[0053] Fig.14A is a schematic diagram of the experimental design used for the TC-1 tumor experiments. Fig. 14B Figure 2 shows the average tumor volume (cm) of TC-1 tumor-bearing mice treated with E7Vax, 4G9, RMP1-14, J43, E7 Vax+4G9, E7 Vax+RMP 1-14, E7 Vax+J43 or not. 3 ) over time (days). The X-axis represents time (days) and the Y-axis represents the average tumor volume (cm 3 ). Fig. 14C : is a line graph showing the survival percentage of TC-1 tumor-bearing mice treated with E7 Vax, 4G9, 4C12, 5C2, RMP 1-14, J43, E7 Vax+4G9, E7Vax+4C12, E7 Vax+5C2, E7 Vax+RMP 1-14, E7 Vax+J43 or not treated over time. The X-axis represents time (days) and the Y-axis represents the survival percentage. DETAILED DESCRIPTION
[0054] I. Definitions
[0055] As used herein, a molecule is said to be able to "immunospecifically bind" to a second molecule if the binding of the molecule to the second molecule exhibits the antibody's specificity and affinity for its cognate antigen. If such binding involves an antigen recognition site of an immunoglobulin molecule, then the antibody is said to be able to immunospecifically bind to a target region or conformation ("epitope") of an antigen. Other antigens are considered to be able to immunospecifically bind to an antigen if they have certain sequence or conformational similarities recognized by the antigen recognition site, such as by, for example, immunoassays, An antibody that immunospecifically binds to a particular antigen may bind to that other antigen with lower affinity, but not to completely unrelated antigens, if the antibody (and its antigen-binding fragment) is determined by a PCR assay or other assays known in the art. However, preferably, the antibody (and its antigen-binding fragment) will not cross-react with other antigens. Antibodies may also bind to other molecules (such as FcR receptors) in a non-immunospecific manner through binding domains in other regions / domains of the molecule that are not involved in the antigen recognition site (such as the Fc region).
[0056] As used herein, a molecule is said to "physiologically specifically bind" a second molecule if such binding exhibits the specificity and affinity of a receptor for its cognate binding ligand. A molecule may be capable of physiologically specifically binding to more than one other molecule.
[0057] As used herein, the term "antibody" is intended to refer to an immunoglobulin molecule having a "variable region" antigen recognition site. The term "variable region" is intended to distinguish such domains of immunoglobulins from domains widely shared by antibodies (such as antibody Fc domains). The variable region includes a "hypervariable region" whose residues are responsible for antigen binding. The hypervariable region includes amino acid residues from a "complementarity determining region" or "CDR" (i.e., generally about residues 24-34 (L1), residues 50-56 (L2), and residues 89-97 (L3) in a light chain variable domain and about residues 27-35 (H1), residues 50-65 (H2), and residues 95-102 (H3) in a heavy chain variable domain; Kabat et al., "Sequences of Proteins of Immunological Interest", 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD. (1991)) and / or those residues from the "hypervariable loops" (i.e., residues 26-32 (L1), residues 50-52 (L2), and residues 91-96 (L3) in the light chain variable domain and residues 26-32 (H1), residues 53-55 (H2), and residues 96-101 (H3) in the heavy chain variable domain; Chothia and Lesk, J. Mol. Biol., vol. 196, pp. 901-917, 1987). "Framework region" or "FR" residues are those variable domain residues other than the hypervariable region residues as herein defined.The term antibody includes monoclonal antibodies, multispecific antibodies, human antibodies, humanized antibodies, synthetic antibodies, chimeric antibodies, camelized antibodies (see, e.g., Muyldermans et al., 2001, Trends Biochem. Sci., Vol. 26, p. 230; Nuttall et al., 2000, Cur. Pharm. Biotech., Vol. 1, p. 253; Reichmann and Muyldermans, 1999, J. Immunol. Meth., Vol. 231, p. 25; International Publications WO 94 / 04678 and WO 94 / 25591; U.S. Pat. No. 6,005,079), single-chain Fv (scFv) (see, e.g., Pluckthun, The Pharmacology of Monoclonal Antibodies, Vol. 113, Rosenburg and Moore, eds., Springer-Verlag, New York, NY), and scFv (see, e.g., Pluckthun, The Pharmacology of Monoclonal Antibodies, Vol. 113, Rosenburg and Moore, eds., Springer-Verlag, New York, NY). York, pp. 269-315 (1994)), single-chain antibodies, disulfide-linked Fv (sdFv), intracellular antibodies and anti-idiotypic (anti-Id) antibodies (including, for example, anti-Id antibodies and antibodies against anti-anti-Id antibodies). Specifically, such antibodies include immunoglobulin molecules of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass.
[0058] As used herein, the term "antigen-binding fragment" of an antibody refers to one or more portions of an antibody that contain the complementarity determining region ("CDR") of the antibody and optionally the framework residues of the "variable region" antigen recognition site of the antibody, and exhibit the ability to immunospecifically bind to an antigen. Such fragments include Fab', F(ab')2, Fv, single chain (ScFv) and mutants thereof, naturally occurring variants, and fusion proteins including the "variable region" antigen recognition site of the antibody, as well as heterologous proteins (e.g., toxins, antigen recognition sites for different antigens, enzymes, receptors or receptor ligands, etc.).
[0059] As used herein, the term "fragment" refers to a peptide or polypeptide that includes an amino acid sequence of at least 5 consecutive amino acid residues, at least 10 consecutive amino acid residues, at least 15 consecutive amino acid residues, at least 20 consecutive amino acid residues, at least 25 consecutive amino acid residues, at least 40 consecutive amino acid residues, at least 50 consecutive amino acid residues, at least 60 consecutive amino acid residues, at least 70 consecutive amino acid residues, at least 80 consecutive amino acid residues, at least 90 consecutive amino acid residues, at least 100 consecutive amino acid residues, at least 125 consecutive amino acid residues, at least 150 consecutive amino acid residues, at least 175 consecutive amino acid residues, at least 200 consecutive amino acid residues, or at least 250 consecutive amino acid residues.
[0060] As used herein, the term "binding molecule" is intended to refer to a molecule that specifically interacts with and binds to a particular target. The target may comprise a biological or small (chemical) molecule. The target molecule may define an antigen or an antigenic portion. Examples of binding molecules include, but are not limited to, antibodies (including monoclonal antibodies, bispecific antibodies, and antibody fragments), fusion proteins, and other antigen binding molecules known to those skilled in the art.
[0061] As used herein, the term "modulation" refers to the ability to change an effect, result or activity (e.g., signal transduction). Such modulation can be agonistic or antagonistic. Antagonistic modulation can be partial (i.e., attenuated but not eliminated), or such activity can be completely eliminated (e.g., neutralized). Modulation can include the internalization of the receptor after antibody binding or the reduction of receptor expression on the target cell. Agonistic modulation can enhance or otherwise increase or enhance activity (e.g., signal transduction). In another embodiment, such modulation can change the nature of the interaction between the ligand and its cognate receptor, thereby changing the nature of the signal transduction caused. For example, a molecule can change the ability of such a molecule to bind to other ligands or receptors by binding to a ligand or receptor, thereby changing its overall activity. Preferably, such modulation will provide a measurable change in immune system activity of at least 10%, more preferably at least 50% of such activity, or at least 2 times, 5 times, 10 times, or still more preferably at least 100 times of such activity.
[0062] The term "substantially" as used in conjunction with or showing an effect is intended to indicate that the observed effect is physiologically or therapeutically relevant. Thus, for example, if the extent of blocking is physiologically or therapeutically relevant (e.g., if the extent of blocking is greater than 60%, greater than 70%, greater than 75%, greater than 80%, greater than 85%, greater than 90%, greater than 95%, or greater than 97% compared to complete blocking), the molecule is able to substantially block the activity of a ligand or receptor. Similarly, if the immunospecificity and characteristic similarity of a molecule to another molecule is greater than 60%, greater than 70%, greater than 75%, greater than 80%, greater than 85%, greater than 90%, greater than 95%, or greater than 97%, such immunospecificity and / or characteristics are considered to be substantially the same).
[0063] As used herein, "co-stimulatory" signals include positive co-stimulatory signals (eg, signals that result in an increase in activity) and negative co-stimulatory signals (eg, signals that result in an inhibition of activity).
[0064] As used herein, the term "derivative" refers to an antibody or antigen-binding fragment thereof that immunospecifically binds to the same target of a parent or reference antibody but differs from the parent or reference antibody or its antigen-binding fragment in amino acid sequence by including one, two, three, four, five or more amino acid substitutions, additions, deletions or modifications relative to the parent or reference antibody or its antigen-binding fragment. Preferably, such derivatives will have substantially the same immunospecificity and / or characteristics as the parent or reference antibody or its antigen-binding fragment, or the same immunospecificity and characteristics. The amino acid substitutions or additions of such derivatives may include naturally occurring (i.e., DNA-encoded) or non-naturally occurring amino acid residues. The term "derivative" includes, for example, chimeric or humanized variants and variants with altered CH1 regions, hinge regions, CH2 regions, CH3 regions or CH4 regions, thereby forming, for example, antibodies with Fc region variants that exhibit enhanced or impaired effectors or binding characteristics, etc.
[0065] As used herein, a "chimeric antibody" is a molecule in which different portions of the antibody are derived from different immunoglobulin molecules, such as an antibody having variable regions derived from a non-human antibody and human immunoglobulin constant regions.
[0066] As used herein, the term "humanized antibody" refers to an immunoglobulin comprising a human framework region and one or more CDRs from a non-human (usually mouse or rat) immunoglobulin. The non-human immunoglobulin providing the CDR is referred to as a "donor", and the human immunoglobulin providing the framework is referred to as an "acceptor". The constant region does not have to be present, but if present, they should be substantially identical to the human immunoglobulin constant region, i.e., at least about 85%-99%, preferably about 95% or higher identity. Therefore, except for possible CDRs, all parts of the humanized immunoglobulin are substantially identical to the corresponding parts of the natural human immunoglobulin sequence. A humanized antibody is an antibody comprising a humanized light chain and a humanized heavy chain immunoglobulin. For example, a humanized antibody will not encompass a typical chimeric antibody, because, for example, the entire variable region of a chimeric antibody is non-human.
[0067] As used herein, the term "endogenous concentration" refers to the level at which a molecule is naturally expressed (ie, in the absence of an expression vector or recombinant promoter) by a cell (which may be a normal cell, a cancer cell, or an infected cell).
[0068] As used herein, the terms "treat," "treating," "treatment," and "therapeutic use" refer to eliminating, alleviating, or ameliorating one or more symptoms of a disease or disorder exacerbated by an anti-PD-1 antibody or antigenic fragment thereof.
[0069] As used herein, a "therapeutically effective amount" refers to an amount of a therapeutic agent sufficient to mediate a clinically relevant elimination, alleviation, or improvement of such symptoms. An effect is clinically relevant if the magnitude of the effect is sufficient to affect the health or prognosis of the receiving subject. A therapeutically effective amount may refer to an amount of a therapeutic agent sufficient to delay or minimize the onset of a disease (e.g., delay or minimize the spread of cancer). A therapeutically effective amount may also refer to an amount of a therapeutic agent that provides a therapeutic benefit in the treatment or management of a disease.
[0070] As used herein, the term "prophylactic agent" refers to an agent that can be used to prevent a condition or disease before any symptoms of such condition or disease are detected. A "prophylactically effective" amount is an amount of a prophylactic agent sufficient to mediate such protection. A prophylactically effective amount may also refer to an amount of a prophylactic agent that provides a prophylactic benefit in the prevention of a disease.
[0071] As used herein, the term "cancer" refers to a tumor caused by abnormal uncontrolled growth of cells. As used herein, cancer clearly includes leukemia and lymphoma. The term "cancer" refers to a disease involving cells that may be transferred to distal sites and exhibit phenotypic traits different from non-cancerous cells (e.g., forming colonies in three-dimensional substrates (such as soft agar) or forming tubular networks or reticular matrix in three-dimensional basement membranes or extracellular matrix preparations). Non-cancerous cells do not form colonies in soft agar, and form different spherical structures in three-dimensional basement membranes or extracellular matrix preparations.
[0072] As used herein, "immune cell" refers to any cell from hematopoietic origin, including but not limited to T cells, B cells, monocytes, dendritic cells, and macrophages.
[0073] As used herein, "valency" refers to the number of available binding sites per molecule.
[0074] As used herein, the terms "immune," "immunological," or "immune" responses are beneficial humoral (antibody-mediated) and / or cellular (mediated by antigen-specific T cells or their secretory products) responses in a recipient patient to a peptide. Such responses may be active responses induced by administration of an immunogen or passive responses induced by administration of antibodies or primed T cells. Presentation of polypeptide epitopes associated with class I or class II MHC molecules activates antigen-specific CD4 + T helper cells and / or CD8 + Cytotoxic T cells, thereby initiating a cellular immune response. This response may also involve the activation of monocytes, macrophages, NK cells, basophils, dendritic cells, astrocytes, microglia, eosinophils, the activation or recruitment of neutrophils or other components of innate immunity. The presence of a cell-mediated immune response can be determined by proliferation assays (CD4 + The relative contributions of humoral and cellular responses to the protective or therapeutic effects of an immunogen can be distinguished by isolating antibodies and T cells from an immunized syngeneic animal and measuring the protective or therapeutic effects in a second subject.
[0075] As used herein, an "immunogenic agent" or "immunogen" is capable of inducing an immune response against itself when administered to a mammal, optionally in combination with an adjuvant.
[0076] As used herein, the terms "individual," "host," "subject," and "patient" are used interchangeably herein and refer to mammals, including but not limited to humans, rodents (such as mice and rats), and other laboratory animals.
[0077] As used herein, the term "polypeptide" refers to an amino acid chain of any length, regardless of whether it is modified (e.g., phosphorylated or glycosylated). The term polypeptide includes proteins and fragments thereof. Polypeptides can be "exogenous", meaning that they are "heterologous", i.e., foreign to the host cell utilized, such as human polypeptides produced by bacterial cells. Polypeptides are disclosed herein as sequences of amino acid residues. These sequences are written from left to right in the direction from the amino terminus to the carboxyl terminus. According to standard nomenclature, amino acid residue sequences are named by three-letter or one-letter codes as follows: alanine (Ala, A), arginine (Arg, R), asparagine (Asn, N), aspartic acid (Asp, D), cysteine (Cys, C), glutamine (Gln, Q), glutamic acid (Glu, E), glycine (Gly, G), histidine (His, H), isoleucine (Ile, I), leucine (Leu, L), lysine (Lys, K), methionine (Met, M), phenylalanine (Phe, F), proline (Pro, P), serine (Ser, S), threonine (Thr, T), tryptophan (Trp, W), tyrosine (Tyr, Y) and valine (Val, V).
[0078] As used herein, the term "variant" refers to a polypeptide or polynucleotide that is different from a reference polypeptide or polynucleotide but retains the necessary properties. A typical variant of a polypeptide is different from another reference polypeptide in amino acid sequence. Typically, the difference is limited so that the sequences of the reference polypeptide and the variant are generally very similar and identical in many regions. The variant and the reference polypeptide may differ in amino acid sequence by one or more modifications (e.g., substitutions, additions and / or deletions). The substituted or inserted amino acid residues may or may not be amino acid residues encoded by the genetic code. The variant of a polypeptide may be naturally occurring, such as an allelic variant, or may be an unknown naturally occurring variant.
[0079] The polypeptide structures of the present disclosure can be modified and altered and still obtain a molecule having similar characteristics to the polypeptide (e.g., conservative amino acid substitutions). For example, certain amino acids can replace other amino acids in the sequence without significant loss of activity. Because the interaction ability and properties of the polypeptide determine the biological functional activity of the polypeptide, certain amino acid sequence substitutions can be made in the polypeptide sequence and still obtain a polypeptide with similar properties.
[0080] In making such changes, the hydropathic index of the amino acid may be considered. The importance of the hydropathic amino acid index in conferring interactive biological function to a polypeptide is generally understood in the art. It is known that certain amino acids can be substituted with other amino acids having a similar hydropathic index or score and still produce a polypeptide with similar biological activity. A hydropathic index has been assigned to each amino acid based on its hydrophobicity and charge characteristics. These indices are: isoleucine (+4.5), valine (+4.2), leucine (+3.8), phenylalanine (+2.8), cysteine / cystine (+2.5), methionine (+1.9), alanine (+1.8), glycine (-0.4), threonine (-0.7), serine (-0.8), tryptophan (-0.9), tyrosine (-1.3), proline (-1.6), histidine (-3.2), glutamate (-3.5), glutamine (-3.5), aspartic acid (-3.5), asparagine (-3.5), lysine (-3.9), and arginine (-4.5).
[0081] It is believed that the relative hydrophilicity of an amino acid determines the secondary structure of the resulting polypeptide, which in turn defines the interaction of the polypeptide with other molecules such as enzymes, substrates, receptors, antibodies, antigens, and cofactors. It is known in the art that an amino acid can be substituted with another amino acid having a similar hydropathic index and still obtain a functionally equivalent polypeptide. In such variations, substitution of amino acids with a hydropathic index within ±2 is preferred, those with a hydropathic index within ±1 are particularly preferred, and those with a hydropathic index within ±0.5 are even more particularly preferred.
[0082] Substitution of similar amino acids can also be made on the basis of hydrophilicity, particularly where the resulting biologically functionally equivalent polypeptides or peptides are intended for use in immunological embodiments. The following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0), lysine (+3.0), aspartic acid (+3.0 ± 1), glutamic acid (+3.0 ± 1), serine (+0.3), asparagine (+0.2), glutamine (+0.2), glycine (0), proline (-0.5 ± 1), threonine (-0.4), alanine (-0.5), histidine (-0.5), cysteine (-1.0), methionine (-1.3), valine (-1.5), leucine (-1.8), isoleucine (-1.8), tyrosine (-2.3), phenylalanine (-2.5), tryptophan (-3.4). It should be understood that one amino acid can be substituted for another amino acid having a similar hydrophilicity value and still result in a biologically equivalent, particularly immunologically equivalent, polypeptide. In such changes, substitution of amino acids whose hydrophilicity values are within ±2 is preferred, those whose hydrophilicity values are within ±1 are particularly preferred, and those whose hydrophilicity values are within ±0.5 are even more particularly preferred.
[0083] As described above, amino acid substitutions are generally based on the relative similarity of the amino acid side chain substituents, such as their hydrophobicity, hydrophilicity, charge, size, etc. Exemplary substitutions taking into account various of the foregoing characteristics are well known to those of skill in the art and include (original residue: exemplary substitutions): (Ala: Gly, Ser), (Arg: Lys), (Asn: Gln, His), (Asp: Glu, Cys, Ser), (Gln: Asn), (Glu: Asp), (Gly: Ala), (His: Asn, Gln), (Ile: Leu, Val), (Leu: Ile, Val), (Lys: Arg), (Met: Leu, Tyr), (Ser: Thr), (Thr: Ser), (Tip: Tyr), (Tyr: Trp, Phe) and (Val: Ile, Leu). Therefore, embodiments of the present disclosure contemplate functional or biological equivalents of the polypeptides described above. Specifically, embodiments of the polypeptides may include variants having about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the polypeptide of interest.
[0084] The term "sequence identity percentage (%)" is defined as the percentage of nucleotides or amino acids in the candidate sequence that are identical to the nucleotides or amino acids in the reference nucleic acid sequence after aligning the sequences and introducing gaps (if necessary) to achieve the maximum sequence identity percentage. Alignment for the purpose of determining sequence identity percentage can be achieved in various ways within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. Suitable parameters for measuring alignment can be determined by known methods, including any algorithm required for achieving maximum alignment over the full length of the compared sequence.
[0085] For the purposes herein, the % sequence identity of a given nucleotide or amino acid sequence C relative to, with or to a given nucleic acid sequence D (which may alternatively be expressed as a given sequence C having or including a certain % sequence identity relative to, with or to a given sequence D) is calculated as follows:
[0086] 100 times the fraction W / Z,
[0087] where W is the number of nucleotides or amino acids scored as identical matches by the sequence alignment program in the program's alignment of C and D, and where Z is the total number of nucleotides or amino acids in D. It will be understood that where the length of sequence C is not equal to the length of sequence D, the % sequence identity of C relative to D will not be equal to the % sequence identity of D relative to C.
[0088] As used herein, the term "pharmaceutically acceptable carrier" encompasses any of the standard pharmaceutical carriers such as phosphate-buffered saline, water, and emulsions (such as oil / water or water / oil emulsions) and various types of wetting agents.
[0089] As used herein, the terms "antigenic determinant" and "epitope" are used interchangeably and refer to a structure recognized by an antibody.
[0090] As used herein, a "conformational epitope" is an epitope that includes a discontinuous portion of the amino acid sequence of an antigen. Antibodies bind to conformational epitopes based on the 3-dimensional surface features, shape, or tertiary structure of the antigen.
[0091] As used herein, a "linear epitope" is an epitope formed by a contiguous sequence of amino acids from an antigen. A linear epitope typically includes about 5 to about 10 contiguous amino acid residues. Antibodies bind to linear epitopes based on the primary sequence of the antigen.
[0092] As used herein, a "paratope," also called an "antigen binding site," is the portion of an antibody that recognizes and binds an antigen.
[0093] II. Composition
[0094] Provided are antibodies and antigen-binding fragments thereof that immunospecifically bind to PD-1. Contrary to the existing paradigm that PD-1 specifically promotes inhibitory immune responses (Riley, J., Immunol Rev., Vol. 229, No. 1, pp. 114-125, 2009), the disclosed antibodies and antigen-binding fragments thereof immunospecifically bind to PD-1 and cause activation signals that activate immune cells rather than inhibit immune cells to be delivered to immune cells.
[0095] A. Programmed death receptor protein 1 (PD-1)
[0096] The disclosed antibodies and antigen-binding fragments thereof immunospecifically bind to PD-1. The antibodies and antigen-binding fragments thereof can bind to PD-1 having, for example, the amino acid sequence provided below.
[0097] The amino acid sequences of human PD-1 and mouse PD-1 are known in the art and include, for example,
[0098] Human PD-1
[0099] MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFSPALLVVTEGDN
[0100] ATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQL
[0101] PNGRDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEV
[0102] PTAHPSPSPRPAGQFQTLVVGVVGGLLGSLVLLVWVLAVICSRAARGTIGA
[0103] RRTGQPLKEDPSAVPVFSVDYGELDFQWREKTPEPPVPCVPEQTEYATIVFPSGMGTSSPARRGSADGPRSAQPLRPEDGHCSWPL (SEQ ID NO: 1), accession number: AJS10360, and the entire text of which is expressly incorporated herein by reference.
[0104] Mouse PD-1
[0105] MWVRQVPWSFTWAVLQLSWQSGWLLEVPNGPWRSLTFYPAWLTVSEGA
[0106] NATFTCSLSNWSEDLMLNWNRLSPSNQTEKQAAFCNGLSQPVQDARFQIIQ
[0107] LPNRHDFHMNILDTRRNDSGIYLCGAISLHPKAKIEESPGAELVVTERILETS
[0108] TRYPSPSPKPEGRFQGMVIGIMSALVGIPVLLLLAWALAVFCSTSMSEARGA
[0109] GSKDDTLKEEPSAAPVPSVAYEELDFQGREKTPELPTACVHTEYATIVFTEGLGASAMGRRGSADGLQGPRPPRHEDGHCSWPL (SEQ ID NO: 2) UniProtKB-Q02242 (PDCD1_MOUSE), and the entire text of which is expressly incorporated herein by reference.
[0110] B. Antibody Composition
[0111] The disclosed anti-PD-1 antibodies or antigen-binding fragments thereof include any class of complete immunoglobulins (i.e., complete antibodies), fragments thereof, and synthetic proteins comprising at least the antigen-binding variable domains of antibodies. In some embodiments, the disclosed antibodies include both the antibody light chain and at least the variable domains of the antibody heavy chain. In other embodiments, such molecules may also include one or more of the CH1 region, hinge region, CH2 region, CH3 region, and CH4 region of the heavy chain (especially the CH1 region and hinge region, or the CH1 region, hinge region, and CH2 region, or the CH1 region, hinge region, CH2 region, and CH3 region). The antibody may be selected from any class of immunoglobulins, including IgM, IgG, IgD, IgA, and IgE, and any isotype, including IgG1, IgG2, IgG3, and IgG4. In some embodiments, the constant domain is a complement fixing constant domain, in which the antibody is expected to exhibit cytotoxic activity, and the class is typically IgG1. In other embodiments, in the absence of such cytotoxic activity, the constant domain may be IgG2 or IgG4. Antibodies may comprise sequences from more than one class or isotype, and selection of particular constant domains to optimize desired effector functions is within the purview of those of ordinary skill in the art.
[0112] The variable domain sequences between antibodies are different, and are used for the binding and specificity of each specific antibody to its specific antigen. However, variability is usually not evenly distributed in the variable domains of antibodies. It is usually concentrated in the three segments called complementary determining regions (CDRs) or hypervariable regions in the light chain and heavy chain variable domains. The more highly conserved part in the variable domain is called framework (FR). The variable domains of natural heavy and light chains each include four FR regions that mainly adopt a β-folded configuration and are connected by three CDRs, and the three CDRs form a loop, which is connected and forms a part of the β-folded structure in some cases. The CDR in each chain is kept together in close proximity by the FR region, and together with the CDR from another chain, it contributes to the formation of the antigen binding site of the antibody.
[0113] Some embodiments provide fragments of anti-PD-1 antibodies with biological activity. These fragments, whether or not linked to other sequences, may include insertions, deletions, substitutions or other selected modifications of specific regions or specific amino acid residues, provided that the activity of the fragment is not significantly altered or impaired compared to the unmodified antibody or antibody fragment.
[0114] Another embodiment provides a single-chain antibody specific for PD-1. Methods for producing single-chain antibodies are well known to those skilled in the art. Single-chain antibodies can be formed by fusing the variable domains of the heavy and light chains together using a short peptide linker to reconstruct the antigen binding site on a single molecule. Single-chain antibody variable fragments (scFv) have been developed without significantly disrupting antigen binding or binding specificity, in which the C-terminus of one variable domain is connected to the N-terminus of another variable domain via a 15 to 25 amino acid peptide or linker. The linker is selected to allow the heavy and light chains to be combined in their proper conformational orientation.
[0115] Another embodiment provides a divalent single-chain variable fragment (di-scFv) that can be engineered by connecting two scFv. This can be accomplished by producing a single peptide chain with two VH regions and two VL regions, thereby producing a series scFv. ScFv can also be designed to have a linker peptide that is too short for the two variable regions to fold together (about five amino acids), thereby forcing the scFv dimerization. This type is referred to as a double antibody. Double antibodies have been shown to have a dissociation constant up to 40 times lower than that of corresponding scFv, which means that they have a much higher affinity to their target. Still shorter joints (one or two amino acids) lead to the formation of trimers (three antibodies). Four antibodies have also been produced. Their affinity to their target is even higher than double antibodies.
[0116] Another embodiment provides a PD-1 specific monoclonal antibody that induces activation signals for immune cells. Monoclonal antibodies can be obtained from a substantially homogeneous antibody population, i.e., the individual antibodies within the population are identical except for possible naturally occurring mutations that may be present in a small subset of antibody molecules. Monoclonal antibodies include "chimeric" antibodies, in which a portion of the heavy chain and / or light chain is identical or homologous to a corresponding sequence in an antibody derived from a particular species or belonging to a particular antibody class or subclass, and the remainder of the one or more chains is identical or homologous to a corresponding sequence in an antibody derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, as long as they exhibit the desired antagonistic activity.
[0117] 1. Chimeric and humanized antibodies
[0118] Another embodiment provides chimeric anti-PD-1 antibodies and antigen-binding fragments thereof comprising one or more of the disclosed sequences, and also provides functional variants thereof that bind to PD-1 and cause activation signals to be transmitted to immune cells expressing PD-1.
[0119] Methods for producing chimeric antibodies are known in the art. See, for example, Morrison, 1985, Science, Vol. 229, p. 1202; Oi et al., 1986, BioTechniques, Vol. 4, p. 214; Gillies et al., 1989, J. Immunol. Methods, Vol. 125, pp. 191-202; U.S. Pat. Nos. 6,311,415, 5,807,715, 4,816,567 and 4,816,397. Chimeric antibodies comprising one or more CDRs from a non-human species and framework regions from a human immunoglobulin molecule can be produced using a variety of techniques known in the art, including, for example, CDR-grafting (EP 239,400; International Publication No. WO 91 / 09967; and U.S. Pat. Nos. 5,225,539, 5,530,101, and 5,585,089), veneer or surface reconstruction (EP 592,106; EP 519,596; Padlan, 1991, Molecular Immunology, Vol. 28, No. 4 / 5, pp. 489-498; Studnicka et al., 1994, Protein Engineering, Vol. 7, p. 805; and Roguska et al., 1994, Proc. Natl. Acad. Sci. USA, Vol. 91, p. 969), and chain shuffling (U.S. Pat. No. 5,565,332).
[0120] The disclosed anti-PD-1 antibodies or antigen-binding fragments thereof can be human or humanized antibodies or antigen-binding fragments thereof. Many non-human antibodies (e.g., non-human antibodies derived from mice, rats, or rabbits) have natural antigenicity in humans and therefore cause adverse immune responses when administered to humans. Therefore, the use of human or humanized antibodies in these methods helps reduce the chance that the antibodies will cause adverse immune responses when administered to humans.
[0121] Transgenic animals (e.g., mice) that are capable of producing a complete human antibody repertoire upon immunization in the absence of endogenous immunoglobulins can be used. For example, homozygous deletions of the antibody heavy chain joining region (J(H)) gene in chimeric and germline mutant mice have been described to result in complete inhibition of endogenous antibody production. Transfer of the human germline immunoglobulin gene array in such germline mutant mice will result in the production of human antibodies upon antigen challenge.
[0122] Optionally, antibodies are produced in other species and "humanized" to be used in the human body. The humanized form of non-human (e.g., mouse) antibodies is a chimeric immunoglobulin, immunoglobulin chain or its fragment (e.g., Fv, Fab, Fab', F(ab')2 or other antigen binding subsequences of antibodies) containing a minimum sequence derived from non-human immunoglobulins. Humanized antibodies include human immunoglobulins (receptor antibodies), wherein the residues of the complementary determining regions (CDRs) of the receptor antibodies are replaced by CDR residues with desired specificity, affinity and ability of non-human species (donor antibodies) (such as mice, rats or rabbits). In some cases, the Fv framework residues of human immunoglobulins are replaced by corresponding non-human residues. Humanized antibodies may also include residues that are neither present in the receptor antibodies nor in the CDR or framework sequences that are imported. Typically, a humanized antibody will comprise substantially all of at least one variable domain, and typically two variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are FR regions of a human immunoglobulin consensus sequence. Optimally, a humanized antibody will also comprise an immunoglobulin constant region (Fc), typically at least a portion of the constant region of a human immunoglobulin.
[0123] Methods for humanizing non-human antibodies are well known in the art, see, e.g., European Patents EP 239,400, EP 592,106, and EP 519,596; International Publications WO 91 / 09967 and WO 93 / 17105; U.S. Patents 5,225,539, 5,530,101, 5,565,332, 5,585,089, 5,766,886, and 6,407,213; and Padlan, 1991, Molecular Immunology, Vol. 28, No. 4 / 5, pp. 489-498; Studnicka et al., 1994, Protein Engineering, Vol. 7, No. 6, pp. 805-814; Roguska et al., 1994, PNAS, Vol. 91, pp. 969-973; Tan et al., 2002, J. Immunol., Vol. 169, pp. 1119-1125; Caldas et al., 2000, Protein Eng., Vol. 13, pp. 353-360; Morea et al., 2000, Methods, Vol. 20, pp. 267-279; Baca et al., 1997, J. Biol. Chem., Vol. 272, pp. 10678-10684; Roguska et al., 1996, Protein Eng., Vol. 9, pp. 895-904; Couto et al., 1995, Cancer Res., Vol. 55 Suppl. No. 23, pp. 5973s-5977s; Couto et al., 1995, Cancer Res., Vol. 55, pp. 1717-1722; Sandhu, 1994, Gene, Vol. 150, pp. 409-410; Pedersen et al., 1994, J. Mol. Biol., Vol. 235, pp. 959-973; Jones et al., 1986, Nature, Vol. 321, pp. 522-525; Reichmann et al., 1988, Nature, Vol. 332, pp. 323-329; and Presta, 1992, Curr. Op. Struct. Biol., Vol. 2, pp. 593-596).
[0124] Generally speaking, humanized antibodies have one or more amino acid residues introduced from non-human sources. These non-human amino acid residues are commonly referred to as "import" residues, which are usually taken from "import" variable domains. Antibody humanization technology generally involves using recombinant DNA technology to manipulate the DNA sequence of one or more polypeptide chains encoding antibody molecules. Humanization can be performed by replacing the corresponding sequence of human antibodies with rodent CDR or CDR sequences. Therefore, the humanized form of non-human antibodies (or its fragment) is a chimeric antibody or fragment, wherein substantially less than complete human variable domains have been replaced by corresponding sequences from non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possible some FR residues are replaced by residues in similar sites in rodent antibodies.
[0125] In order to reduce antigenicity, it may be very important to select the human variable domains (both light and heavy chains) for the preparation of humanized antibodies. According to the "best fit" method, the sequence of the rodent antibody variable domain is screened for the entire library of known human variable domain sequences. Then, the human sequence closest to the rodent sequence is accepted as the human framework (FR) of humanized antibodies. Another method uses the specific framework of the consensus sequence of all human antibodies derived from the specific subgroup of light chain or heavy chain. The same framework can be used for several different humanized antibodies.
[0126] It is further important to humanize antibodies while retaining high affinity for antigens and other favorable biological properties. In order to achieve this goal, humanized antibodies can be prepared by using the three-dimensional model analysis of parental sequences and various conceptual humanized products of parental and humanized sequences. The three-dimensional immunoglobulin model is generally available and is familiar to those skilled in the art. Available computer programs can be used to illustrate and display the possible three-dimensional conformational structure of selected candidate immunoglobulin sequences. The detection of these displays enables the analysis of the possible effects of residues in the functioning of candidate immunoglobulin sequences, i.e., the analysis of the residues that affect the ability of candidate immunoglobulins and their antigen binding. In this way, FR residues can be selected and combined from consensus sequences and imported sequences, thereby obtaining desired antibody characteristics, such as the affinity increased to one or more target antigens. Usually, CDR residues directly and mainly participate in affecting antigen binding.
[0127] People, humanized or chimeric antibody derivatives may include at least one and generally substantially all of two variable domains, wherein all or substantially all of the CDR regions correspond to the CDR regions of non-human immunoglobulins (i.e., donor antibodies) and all or substantially all of the framework regions are CDR regions of human immunoglobulin consensus sequences. Such antibodies may also include at least a portion of an immunoglobulin constant region (Fc), typically at least a portion of a constant region of a human immunoglobulin. The constant domains of such antibodies may be selected according to the expected function of the antibody (particularly the effector functions that may be required). In some embodiments, the constant domains of such antibodies are or may include human IgA, IgD, IgE, IgG or IgM domains. In a specific embodiment, when humanized antibody derivatives are intended for therapeutic use and antibody effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activity are required, human IgG constant domains, especially constant domains of IgG1 and IgG3 isotypes are used. In alternative embodiments, when the antibody is intended for therapeutic purposes and antibody effector functions are not required, IgG2 and IgG4 isotypes are used. Fc constant domains comprising one or more amino acid modifications that alter antibody effector functions are such as those disclosed in U.S. Patent Application Publications 2005 / 0037000 and 2005 / 0064514.
[0128] The framework region and CDR region of humanized antibodies do not need to correspond exactly to the parent sequence, for example, donor CDR or consensus framework can be mutated by substitution, insertion or deletion of at least one residue, so that CDR or framework residues correspond neither to consensus antibody nor to donor antibody at this site. In some embodiments, such mutations are not extensive. Usually, at least 75%, more usually 90% or greater than 95% of humanized antibody residues will correspond to the residues of parent framework region (FR) and CDR sequences.Humanized antibodies can be produced using a variety of techniques known in the art, including but not limited to CDR-grafting (European Patent EP 239,400; International Publication WO 91 / 09967; and U.S. Patents 5,225,539, 5,530,101, and 5,585,089), veneer or surface reconstruction (European Patent EP 592,106 and EP 519,596; Padlan, 1991, Molecular Immunology, Vol. 28, No. 4 / 5, pp. 489-498; Studnicka et al., 1994, Protein Engineering, Vol. 7, No. 6, pp. 805-814; and Roguska et al., 1994, Proc. Natl. Acad. Sci., Vol. 91, pp. 969-973), chain shuffling (U.S. Pat. No. 5,565,332), and disclosed techniques in the following references: for example, U.S. Pat. Nos. 6,407,213, 5,766,886, 5,585,089, International Publication WO 9317105, Tan et al., 2002, J. Immunol., Vol. 169, pp. 1119-1125, Caldas et al., 2000, Protein Eng., Vol. 13, pp. 353-360, Morea et al., 2000, Methods, Vol. 20, pp. 267-279, Baca et al., 1997, J. Biol. Chem., Vol. 272, pp. 10678-10684, Roguska et al., 1996, Protein Eng., Vol. 9, pp. 895-904, Couto et al., 1995, Cancer Res., Vol. 55, Suppl. No. 23, pp. 5973s-5977s, Couto et al., 1995, Cancer Res., Vol. 55, pp. 1717-1722, Sandhu, 1994, Gene, Vol. 150, pp. 409-410, Pedersen et al., 1994, J. Mol. Biol., Vol. 235, pp. 959-973, Jones et al., 1986, Nature, Vol. 321, pp. 522-525, Riechmann et al., 1988, Nature, Vol. 332, p. 323, and Presta, 1992, Curr. Op. Struct. Biol., Vol. 2, pp. 593-596.
[0129] Typically, the framework residues in the framework region will be replaced by the corresponding residues from the CDR donor antibody to change (e.g., improve) antigen binding. These framework substitutions are identified by methods well known in the art, such as by modeling the interaction of CDR and framework residues to identify framework residues important for antigen binding, and by sequence comparison to identify uncommon framework residues at specific positions. (See, e.g., Queen et al., U.S. Patent No. 5,585,089; U.S. Publication Nos. 2004 / 0049014 and 2003 / 0229208; U.S. Patent Nos. 6,350,861, 6,180,370, 5,693,762, 5,693,761, 5,585,089 and 5,530,101 and Riechmann et al., 1988, Nature, Vol. 332, p. 323).
[0130] The disclosed human, chimeric or humanized derivatives of the mouse anti-human Siglec-15 antibodies can be used in human in vivo methods. Mouse antibodies or antibodies of other species can be advantageously used for many purposes (e.g., in vitro or in situ detection assays, acute in vivo uses, etc.). Such human or humanized antibodies may include amino acid residue substitutions, deletions or additions in one or more non-human CDR5s. When compared to non-derivatized humanized antibodies, humanized antibody derivatives may have substantially the same binding, stronger binding or weaker binding. In specific embodiments, one, two, three, four or five amino acid residues of the CDR have been substituted, deleted or added (i.e., mutated). Fully human antibodies are particularly suitable for therapeutic treatment of human subjects.
[0131] Such human antibodies can be prepared by a variety of methods known in the art, including phage display methods using antibody libraries derived from human immunoglobulin sequences (see U.S. Pat. Nos. 4,444,887 and 4,716,111; and International Publications WO 98 / 46645, WO 98 / 50433, WO 98 / 24893, WO 98 / 16654, WO 96 / 34096, WO 96 / 33735, and WO 91 / 10741). Such human antibodies can be produced using transgenic mice that are unable to express functional endogenous immunoglobulins but can express human immunoglobulin genes.
[0132] For example, human heavy chain and light chain immunoglobulin gene complexes can be introduced randomly or introduced into mouse embryonic stem cells by homologous recombination. Alternatively, in addition to human heavy chain and light chain genes, human variable regions, constant regions and diversity regions can also be introduced into mouse embryonic stem cells. Mouse heavy chain and light chain immunoglobulin genes can be separated from or simultaneously lost function by homologous recombination to introduce human immunoglobulin loci. Specifically, the homozygous deletion in the JH region prevents the production of endogenous antibodies. The modified embryonic stem cells are amplified and microinjected into blastocysts to produce chimeric mice. Chimeric mice are then cultivated to produce homozygous progeny expressing human antibodies. Conventional methods are used and transgenic mice are immunized with selected antigens (e.g., all or part of a polypeptide). Using conventional hybridoma technology (see, e.g., U.S. Patent No. 5,916,771), monoclonal antibodies against antigens can be obtained from immune transgenic mice. The human immunoglobulin transgene carried by transgenic mice is rearranged during B cell differentiation, and then undergoes class switching and somatic mutation. Therefore, using this technology, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar (1995, Int. Rev. Immunol., Vol. 13, pp. 65-93, which is incorporated herein by reference in its entirety). For a detailed discussion of the technology for producing human antibodies and human monoclonal antibodies and the scheme for producing such antibodies, see, for example, International Publications WO 98 / 24893, WO 96 / 34096 and WO 96 / 33735; and U.S. Patents 5,413,923, 5,625,126, 5,633,425, 5,569,825, 5,661,016, 5,545,806, 5,814,318 and 5,939,598, which are incorporated herein by reference in their entirety. Alternatively, companies can be hired to provide human antibodies against the antigen of choice using techniques similar to those described above.
[0133] The DNA sequence encoding the human receptor framework sequence includes, but is not limited to, FR segments from human germline VH segments VH1-18 and JH6 and human germline VL segments VK-A26 and JK4. In a specific embodiment, one or more CDRs are inserted into the framework region using conventional recombinant DNA techniques. The framework region can be a naturally occurring or shared framework region, as well as a human framework region (for a list of human framework regions, see, for example, Chothia et al., 1998, "Structural Determinants In The Sequences Of Immunoglobulin Variable Domain", J. Mol. Biol., Vol. 278, pp. 457-479).
[0134] C. Antibody Sequence
[0135] 1.4C12 heavy chain sequence
[0136] One embodiment provides a mouse monoclonal antibody or an antigen-binding fragment thereof isolated from hybridoma 4C12.
[0137] Another embodiment provides an antibody or antigen-binding fragment thereof having a heavy chain encoded by a nucleic acid having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to:
[0138]
[0139]
[0140] The underlined sequences correspond to the complementarity determining regions (CDRs). The double underlined sequences correspond to the constant regions. The dotted underlined sequences correspond to the leader sequences.
[0141] The nucleic acid may be in a vector (eg, an expression vector). The nucleic acid may be extrachromosomal when inserted into a host cell (eg, a chromosome of a Chinese hamster ovary cell).
[0142] One embodiment provides an antibody or antigen-binding fragment thereof having a heavy chain whose amino acid sequence has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to:
[0143]
[0144] Single underlining corresponds to the leader sequence. Double underlining corresponds to the CDRs, and dotted underlining corresponds to the constant regions.
[0145] Another embodiment provides an antibody or antigen-binding fragment thereof having a heavy chain without a leader sequence, the amino acid sequence of the heavy chain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity with:
[0146]
[0147] Double underlining corresponds to CDRs and dashed underlining corresponds to constant regions.
[0148] The amino acid sequence of CDR1 of the 4C12 heavy chain is SYWMH (SEQ ID NO: 6).
[0149] The amino acid sequence of CDR2 of the 4C12 heavy chain is RIHPSDSDTNYNQKFKG (SEQ ID NO: 7).
[0150] The amino acid sequence of CDR3 of the 4C12 heavy chain is YGNYASGFAY (SEQ ID NO: 8).
[0151] One embodiment provides an antibody or antigen-binding fragment thereof having a heavy chain according to SEQ ID NO: 4 or 5.
[0152] Another embodiment provides an antibody or antigen-binding fragment thereof having a heavy chain encoded by a nucleic acid having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO:3.
[0153] One embodiment provides an antibody having three different CDRs selected from the group consisting of: SEQ ID NOs: 6, 7, and 8.
[0154] 2.4C12 light chain sequence
[0155] Another embodiment provides an antibody or antigen-binding fragment thereof having a light chain encoded by a nucleic acid having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to:
[0156]
[0157]
[0158] The dotted underline represents the leader sequence. The single underline represents the CDR. The double underline represents the constant region.
[0159] The nucleic acid may be in a vector (eg, an expression vector). The nucleic acid may be extrachromosomal when inserted into a host cell (eg, a chromosome of a Chinese hamster ovary cell).
[0160] Another embodiment provides an antibody or antigen-binding fragment thereof having a light chain whose amino acid sequence has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to:
[0161]
[0162] Underline represents leader sequence. Double underline represents CDR. Dashed underline represents constant region.
[0163] Another embodiment provides an antibody or antigen-binding fragment thereof having a light chain without a leader sequence, the light chain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to:
[0164]
[0165] Double underlines represent CDRs. Dashed underlines represent constant regions.
[0166] The amino acid sequence of CDR1 of the 4C12 light chain is KASQDVSTAVA (SEQ ID NO: 12).
[0167] The amino acid sequence of CDR2 of the 4C12 light chain is WASTRHT (SEQ ID NO: 13).
[0168] The amino acid sequence of CDR3 of the 4C12 light chain is QQHYSTPWT (SEQ ID NO: 14).
[0169] One embodiment provides an antibody or antigen-binding fragment thereof having a light chain that has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO: 10 or 11.
[0170] Another embodiment provides an antibody or antigen-binding fragment thereof having a light chain encoded by a nucleic acid having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO:9.
[0171] One embodiment provides an antibody having three different CDRs selected from the group consisting of: SEQ ID NOs:12, 13, and 14.
[0172] Another embodiment provides an antibody or antigen-binding fragment thereof having a heavy chain and a light chain or a combination of a heavy chain and a light chain, wherein the amino acid sequence of the heavy chain has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity with SEQ ID NO:4 or 5, and the amino acid sequence of the light chain has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity with SEQ ID NO:10 or 11.
[0173] Another embodiment provides an antibody or antigen-binding fragment thereof having three different heavy chain CDRs and three different light chain CDRs, wherein the amino acids of the three different heavy chain CDRs are selected from the group consisting of: SEQ ID NOs: 6, 7 and 8, and the amino acids of the three different light chain CDRs are selected from the group consisting of: SEQ ID NOs: 12, 13 and 14.
[0174] 3.2B5 heavy chain sequence
[0175] One embodiment provides a mouse monoclonal antibody or an antigen-binding fragment thereof isolated from hybridoma 2B5.
[0176] Another embodiment provides an antibody or antigen-binding fragment thereof having a heavy chain encoded by a nucleic acid having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to:
[0177]
[0178]
[0179] The underlined sequences correspond to the complementarity determining regions (CDRs). The double underlined sequences correspond to the constant regions. The dotted underlined sequences correspond to the leader sequences.
[0180] The nucleic acid may be in a vector (eg, an expression vector). The nucleic acid may be extrachromosomal when inserted into a host cell (eg, a chromosome of a Chinese hamster ovary cell).
[0181] One embodiment provides an antibody or antigen-binding fragment thereof having a heavy chain whose amino acid sequence has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to:
[0182]
[0183] Single underlining corresponds to the leader sequence. Double underlining corresponds to the CDRs, and dotted underlining corresponds to the constant regions.
[0184] Another embodiment provides an antibody or antigen-binding fragment thereof having a heavy chain without a leader sequence, the amino acid sequence of the heavy chain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity with:
[0185]
[0186]
[0187] Double underlining corresponds to CDRs and dashed underlining corresponds to constant regions.
[0188] The amino acid sequence of CDR1 of the 2B5 heavy chain is NYLIE (SEQ ID NO: 18).
[0189] The amino acid sequence of CDR2 of the 2B5 heavy chain is VINPGSGGTNYNEKFKG (SEQ ID NO: 19).
[0190] The amino acid sequence of CDR3 of the 2B5 heavy chain is SAQAPDY (SEQ ID NO: 20).
[0191] One embodiment provides an antibody or antigen-binding fragment thereof having a heavy chain according to SEQ ID NO: 16 or 17.
[0192] Another embodiment provides an antibody or antigen-binding fragment thereof having a heavy chain encoded by a nucleic acid having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO:15.
[0193] One embodiment provides an antibody having three different CDRs selected from the group consisting of: SEQ ID NOs: 18, 19 and 20.
[0194] 4.2B5 light chain sequence
[0195] Another embodiment provides an antibody or antigen-binding fragment thereof having a light chain encoded by a nucleic acid having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to:
[0196]
[0197] The dotted underline represents the leader sequence. The single underline represents the CDR. The double underline represents the constant region.
[0198] The nucleic acid may be in a vector (eg, an expression vector). The nucleic acid may be extrachromosomal when inserted into a host cell (eg, a chromosome of a Chinese hamster ovary cell).
[0199] Another embodiment provides an antibody or antigen-binding fragment thereof having a light chain whose amino acid sequence has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to:
[0200]
[0201]
[0202] Underline represents leader sequence. Double underline represents CDR. Dashed underline represents constant region.
[0203] Another embodiment provides an antibody or antigen-binding fragment thereof having a light chain without a leader sequence, the light chain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to:
[0204]
[0205] Double underlines represent CDRs. Dashed underlines represent constant regions.
[0206] The amino acid sequence of CDR1 of the 2B5 light chain is KASQDVSTAVA (SEQ ID NO: 24).
[0207] The amino acid sequence of CDR2 of the 2B5 light chain is WASTRHT (SEQ ID NO: 13).
[0208] The amino acid sequence of CDR3 of the 2B5 light chain is QQHYSTPWT (SEQ ID NO: 25).
[0209] One embodiment provides an antibody or antigen-binding fragment thereof having a light chain that has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO:22 or 23.
[0210] Another embodiment provides an antibody or antigen-binding fragment thereof having a light chain encoded by a nucleic acid having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO:21.
[0211] One embodiment provides an antibody having three different CDRs selected from the group consisting of: SEQ ID NOs: 24, 13, and 25.
[0212] Another embodiment provides an antibody or antigen-binding fragment thereof having a heavy chain and a light chain or a combination of a heavy chain and a light chain, wherein the amino acid sequence of the heavy chain has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity with SEQ ID NO: 16 or 17, and the amino acid sequence of the light chain has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity with SEQ ID NO: 22 or 23.
[0213] Another embodiment provides an antibody or an antigen-binding fragment thereof having three different heavy chain CDRs and three different light chain CDRs, wherein the amino acids of the three different heavy chain CDRs are selected from the group consisting of: SEQ ID NOs: 18, 19 and 20, and the amino acids of the three different light chain CDRs are selected from the group consisting of: SEQ ID NOs: 24, 13 and 25.
[0214] 6.4G9 heavy chain sequence
[0215] One embodiment provides a mouse monoclonal antibody or an antigen-binding fragment thereof isolated from hybridoma 4G9.
[0216] Another embodiment provides an antibody or antigen-binding fragment thereof having a heavy chain encoded by a nucleic acid having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to:
[0217]
[0218]
[0219] The underlined sequences correspond to the complementarity determining regions (CDRs). The double underlined sequences correspond to the constant regions. The dotted underlined sequences correspond to the leader sequences.
[0220] The nucleic acid may be in a vector (eg, an expression vector). The nucleic acid may be extrachromosomal when inserted into a host cell (eg, a chromosome of a Chinese hamster ovary cell).
[0221] One embodiment provides an antibody or antigen-binding fragment thereof having a heavy chain whose amino acid sequence has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to:
[0222]
[0223] Single underlining corresponds to the leader sequence. Double underlining corresponds to the CDRs, and dotted underlining corresponds to the constant regions.
[0224] Another embodiment provides an antibody or antigen-binding fragment thereof having a heavy chain without a leader sequence, the amino acid sequence of the heavy chain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity with:
[0225]
[0226]
[0227] Double underlining corresponds to CDRs and dashed underlining corresponds to constant regions.
[0228] The amino acid sequence of CDR1 of the 4G9 heavy chain is TYGMT (SEQ ID NO: 29).
[0229] The amino acid sequence of CDR2 of the 4G9 heavy chain is WINTYSGVPTYADDFKG (SEQ ID NO: 30).
[0230] The amino acid sequence of CDR3 of the 4G9 heavy chain is GGRGFAY (SEQ ID NO: 31).
[0231] One embodiment provides a 4G9 antibody or an antigen-binding fragment thereof having a heavy chain according to SEQ ID NO: 27 or 28.
[0232] Another embodiment provides a 4G9 antibody or antigen-binding fragment thereof having a heavy chain encoded by a nucleic acid having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO:26.
[0233] One embodiment provides a 4G9 antibody having three different CDRs selected from the group consisting of: SEQ ID NOs: 29, 30, and 31.
[0234] 7.4G9 light chain sequence
[0235] Another embodiment provides an antibody or antigen-binding fragment thereof having a light chain encoded by a nucleic acid having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to:
[0236]
[0237]
[0238] The dotted underline represents the leader sequence. The single underline represents the CDR. The double underline represents the constant region.
[0239] The nucleic acid may be in a vector (eg, an expression vector). The nucleic acid may be extrachromosomal when inserted into a host cell (eg, a chromosome of a Chinese hamster ovary cell).
[0240] Another embodiment provides an antibody or antigen-binding fragment thereof having a light chain whose amino acid sequence has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to:
[0241]
[0242] Underline represents leader sequence. Double underline represents CDR. Dashed underline represents constant region.
[0243] Another embodiment provides an antibody or antigen-binding fragment thereof having a light chain without a leader sequence, the light chain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to:
[0244]
[0245] Double underlines represent CDRs. Dashed underlines represent constant regions.
[0246] The amino acid sequence of CDR1 of the 4G9 light chain is RASQSIGTSIH (SEQ ID NO: 35).
[0247] The amino acid sequence of CDR2 of the 4G9 light chain is YASESIS (SEQ ID NO: 36).
[0248] The amino acid sequence of CDR3 of the 4G9 light chain is QQSNSWPYT (SEQ ID NO: 37).
[0249] One embodiment provides a 4G9 antibody or an antigen-binding fragment thereof having a light chain that has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO:33 or 34.
[0250] Another embodiment provides a 4G9 antibody or antigen-binding fragment thereof having a light chain encoded by a nucleic acid having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO:32.
[0251] One embodiment provides a 4G9 antibody having three different CDRs selected from the group consisting of: SEQ ID NOs: 35, 36, and 37.
[0252] Another embodiment provides an antibody or antigen-binding fragment thereof having a heavy chain and a light chain or a combination of a heavy chain and a light chain, wherein the amino acid sequence of the heavy chain has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity with SEQ ID NO: 27 or 28, and the amino acid sequence of the light chain has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity with SEQ ID NO: 33 or 34.
[0253] Another embodiment provides a 4G9 antibody or an antigen-binding fragment thereof having three different heavy chain CDRs and three different light chain CDRs, wherein the amino acids of the three different heavy chain CDRs are selected from the group consisting of: SEQ ID NOs: 29, 30 and 31, and the amino acids of the three different light chain CDRs are selected from the group consisting of: SEQ ID NOs: 35, 36 and 37.
[0254] D. PD-1 Activation Epitope
[0255] Disclosed herein are epitope-specific PD-1 binding moieties. In one embodiment, the disclosed binding moieties immunospecifically bind to PD-1 and activate PD-1-mediated signaling.
[0256] The disclosed PD-1 epitope is formed by amino acids 96-110 of SEQ ID NO: 1 and has the following amino acid sequence:
[0257] TYLCGAISLAPKAQI (SEQ ID NO:38).
[0258] 1. Antibodies
[0259] One embodiment provides an antibody or epitope-binding fragment thereof that immunospecifically binds to SEQ ID NO: 38 on the surface of an immune cell and activates the immune cell. In one embodiment, the preferred immune cell is a T cell, more specifically a CD8 + In another embodiment, the antibody or epitope-binding fragment thereof immunospecifically binds to SEQ ID NO: 38 of PD-1 on the surface of an immune cell, and promotes or induces an activation signal through PD-1 to activate the immune cell.
[0260] The epitope-specific antibody can be a monoclonal antibody, a humanized antibody, a human antibody, a mouse antibody, a chimeric antibody, or a fragment thereof. Exemplary antibodies and methods for their generation are discussed below.
[0261] 2. Fusion Protein
[0262] In one embodiment, the epitope-specific PD-1 binding portion is a fusion protein. All or part of one or more of the PD-1 epitope antibodies or epitope binding fragments disclosed above may be coupled to other polypeptides to form a fusion protein. The fusion polypeptide has a first fusion partner, which includes all or part of one or more of the disclosed PD-1 epitope antibodies or epitope binding fragments fused directly to the second polypeptide or fused to the second polypeptide through a linker peptide sequence fused to the second polypeptide. The fusion protein optionally contains a domain for dimerizing or multimerizing two or more fusion proteins. The peptide / polypeptide linker domain may be a separate domain or may be included in one of the other domains (the first polypeptide or the second polypeptide) of the fusion protein. Similarly, the domain for dimerizing or multimerizing the fusion protein may be a separate domain or may be included in one of the other domains (the first polypeptide, the second polypeptide, or the peptide / polypeptide linker domain) of the fusion protein. In one embodiment, the dimerization / multimerization domain and the peptide / polypeptide linker domain are the same.
[0263] The fusion proteins disclosed herein have Formula I:
[0264] N-R1-R2-R3-C
[0265] Wherein "N" represents the N-terminus of the fusion protein, "C" represents the C-terminus of the fusion protein, "R1" is all or part of one of the disclosed PD-1 epitope antibodies or epitope-binding fragments, or a functional variant or fragment thereof, "R2" is an optional peptide / polypeptide linker domain, and "R3" is a second polypeptide. Alternatively, R3 is all or part of one of the disclosed PD-1 epitope antibodies or epitope-binding fragments, or a functional variant or fragment thereof, and R1 is a second polypeptide.
[0266] Dimerization or multimerization can occur between or among two or more fusion proteins through a dimerization or multimerization domain. Alternatively, the dimerization or multimerization of the fusion protein can occur through chemical cross-linking. The dimer or multimer formed can be a homodimer / homomultimer or a heterodimer / heteromultimer.
[0267] 3. Aptamer
[0268] In some embodiments, the epitope-specific binding moiety is an aptamer. An aptamer is a molecule that preferably interacts with a target molecule in a particular manner. In one embodiment, an aptamer binds to SEQ ID NO:38 on the surface of an immune cell and promotes or induces an activation signal to activate immune cells through PD-1. Typically, an aptamer is a small nucleic acid with a length range of 15-50 bases that folds into a determined secondary and tertiary structure, such as a stem-loop or a G-quadruplex. An aptamer can bind to a protein, a cell, a small organic molecule, or a peptide. An aptamer can bind to small molecules such as ATP and basophilic theanine and macromolecules such as reverse transcriptase and thrombin. An aptamer can bind to a target molecule very tightly with a Kd less than 10-12M. Preferably, an aptamer binds to a target molecule with a Kd less than 10-6, 10-8, 10-10, or 10-12. An aptamer can bind to a target molecule with a very high degree of specificity. For example, aptamers have been isolated that differ by more than 10,000-fold in binding affinity between a target molecule and another molecule that differs at only a single position on the molecule. Preferably, the Kd of the aptamer to the target molecule is at least 10, 100, 1000, 10,000, or 100,000-fold lower than its Kd to a background binding molecule. For example, when performing a polypeptide comparison, the background molecule is preferably a different polypeptide. Representative examples of how to prepare and use aptamers to bind to a variety of different target molecules are known in the art.
[0269] 4. Small molecules
[0270] In some embodiments, the epitope-specific binding moiety may be a small molecule. The term "small molecule" generally refers to a small organic compound having a molecular weight greater than about 100 to less than about 2,500 Daltons, preferably between 100 and 2000, more preferably between about 100 to about 1250, more preferably between about 100 to about 1000, more preferably between about 100 to about 750, more preferably between about 200 to about 500 Daltons. Small molecule agonists of the activation epitope of PD-1 can be identified using conventional screening methods. In some embodiments, the screening assay may include random screening of a large library of test compounds. The assay may include determining the immune response induced by PD-1 or the activation of T cells.
[0271] E. Pharmaceutical Compositions
[0272] Pharmaceutical compositions comprising the disclosed antibodies and antigen-binding fragments thereof are provided. Pharmaceutical compositions containing the antibodies and antigen-binding fragments thereof can be used for parenteral (intramuscular, intraperitoneal, intravenous (IV) or subcutaneous injection) administration.
[0273] In some in vivo methods, the compositions disclosed herein are administered to a subject in a therapeutically effective amount. As used herein, the term "effective amount" or "therapeutically effective amount" refers to a dose sufficient to treat, inhibit or alleviate one or more symptoms of the disease being treated or otherwise provide a desired pharmacological and / or physiological effect. The exact dose will vary according to a variety of factors, such as subject-dependent variables (e.g., age, immune system health, etc.), the disease, and the treatment being performed.
[0274] For disclosed antibodies and Fabs thereof, as further studies are conducted, information about suitable dosage levels for treating various conditions in various patients will be available, and those of ordinary skill will be able to determine the correct dosage in light of the treatment context, the age of the recipient, and the general health of the patient. The selected dosage depends on the desired therapeutic effect, route of administration, and desired duration of treatment. For disclosed antibodies and Fabs thereof, dosage levels of 0.001 to 20 mg / kg body weight are usually administered to mammals every day. Typically, for intravenous injection or infusion, the dosage can be lower.
[0275] In certain embodiments, the antibody and antigen-binding fragments thereof are administered locally, for example by direct injection into the site to be treated. Typically, injection results in an increase in the local concentration of the immunomodulator composition, which is higher than that achievable with systemic administration. The immunomodulator composition may be combined with a matrix as described above to help increase the local concentration of the polypeptide composition by reducing passive diffusion of the polypeptide from the site to be treated.
[0276] 1. Preparations for parenteral administration
[0277] In some embodiments, the composition containing the disclosed antibody and Fab is administered with an aqueous solution by parenteral injection. The preparation can also be in the form of a suspension or emulsion. Generally, a pharmaceutical composition comprising an effective amount of an antibody or Fab thereof and optionally comprising a pharmaceutically acceptable diluent, preservative, solubilizer, emulsifier, adjuvant and / or carrier is provided. Such compositions optionally include one or more of the following: diluent, sterile water, various buffer contents (e.g., Tris-HCl, acetate, phosphate), pH and ionic strength buffered saline; and additives, such as detergents and solubilizers (e.g., TWEEN 20 (polysorbate-20), TWEEN 80 (polysorbate-80)), antioxidants (e.g., ascorbic acid, sodium pyrosulfite) and preservatives (e.g., thimerosal, benzyl alcohol) and filler materials (e.g., lactose, mannitol). Examples of non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils (such as olive oil and corn oil), gelatin, and injectable organic esters (such as ethyl oleate). The formulation can be lyophilized and redissolved / resuspended prior to use. The formulation can be sterilized, for example, by filtering through a bacteria-retaining filter, by incorporating a sterilizing agent into the composition, by irradiating the composition, or by heating the composition.
[0278] 2. Oral administration preparations
[0279] In some embodiments, antibody compositions are formulated for oral delivery. The antibodies of the oral dosage form are resistant to proteolysis, and a larger proportion of immunoreactive antibodies can be delivered locally in the gastrointestinal tract to treat infection, or allow antibody absorption to treat or prevent systemic disease (Reilly, RM et al., Clin Pharmacokinet., Vol. 32, No. 4, pp. 313-323 (1997); Victoria S Jasion and Bruce P Burnett, Nutr J., Vol. 14, p. 22 (2015); and Philippart, M. et al., Drug Res (Stuttg), Vol. 66, No. 03, pp. 113-120 (2016)).
[0280] Oral solid dosage forms are generally described in Chapter 89 of Remington's Pharmaceutical Sciences, 18th edition, 1990 (Mack Publishing Co. Easton Pa. 18042). Solid dosage forms include tablets, capsules, pills, lozenges or lozenges, cachets, pills, powders or granules, or the material is incorporated into a granular preparation or liposome of a polymer compound such as polylactic acid, polyglycolic acid, etc. Such compositions can affect the disclosed physical state, stability, in vivo release rate, and in vivo clearance rate. See, for example, Remington's Pharmaceutical Sciences, 18th edition, (1990, Mack Publishing Co., Easton, Pa. 18042) pages 1435-1712, which is incorporated herein by reference. The composition can be prepared in liquid form, or can be in the form of a dry powder (e.g., lyophilized). Liposomes or protein-like encapsulation can be used to formulate the composition. Liposome encapsulation can be used, and liposomes can be derivatized with various polymers (e.g., U.S. Pat. No. 5,013,556). See also Marshall, K., GS Banker and CT Rhodes, ed., Modern Pharmaceutics, Chapter 10, 1979. Typically, the formulation will include the peptide (or its chemically modified form) and an inert ingredient that protects the peptide in the gastric environment and releases the biologically active substance in the intestine.
[0281] Antibodies and their antigen-binding fragments can be chemically modified to make oral delivery of derivatives effective. Generally, the chemical modification envisioned is that at least one portion is attached to the component molecule itself, wherein the portion allows absorption from the stomach or intestine into the bloodstream or directly absorbed into the intestinal mucosa. It is also desirable to increase the overall stability of one or more components and increase the in vivo circulation time. PEGylation is an exemplary chemical modification for pharmaceutical use. Other moieties that may be used include propylene glycol, copolymers of ethylene glycol and propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, polyproline, poly-1,3-dioxolane and poly-1,3,6-trioxane [see, e.g., Abuchowski and Davis (1981) "Soluble Polymer-Enzyme Adducts", in Enzymes as Drugs, Hocenberg and Roberts, eds., (Wiley-Interscience: New York, NY) pp. 367-383; and Newmark et al. (1982) J. Appl. Biochem., Vol. 4, pp. 185-189].
[0282] Another embodiment provides liquid dosage forms for oral administration, including pharmaceutically acceptable emulsions, solutions, suspensions and syrups, which may contain other components including inert diluents, adjuvants (such as wetting agents, emulsifying agents and suspending agents) as well as sweeteners, flavoring agents and perfuming agents.
[0283] For oral formulations, the location of release can be the stomach, small intestine (duodenum, jejunum or ileum) or large intestine. In some embodiments, release by protecting the agent (or derivative) or by releasing the agent (or derivative) outside the gastric environment (such as in the intestine) will avoid the harmful effects of the gastric environment. In order to ensure complete gastric resistance, an impermeable coating at least pH 5.0 is essential. Examples of more common inert ingredients used as enteric coatings include: cellulose acetate trimellitate (CAT), hydroxypropyl methylcellulose phthalate (HPMCP), HPMCP 50, HPMCP 55, vinyl acetate phthalate (PVAP), Eudragit L30D TM 、Aquateric TM 、Cellulose acetate phthalate (CAP), EudragitL TM 、Eudragit S TM and Shellac TM These coatings can be used as hybrid films.
[0284] 3. Controlled delivery polymer matrix
[0285] The antibodies and antigen binding fragments thereof disclosed herein can also be administered in the form of controlled release formulations. The antibodies and antigen binding fragments thereof can be incorporated into an inert matrix such as a gel that allows release by diffusion or leaching mechanisms. Slowly degradable matrices can also be incorporated into the formulation. Another form of controlled release is based on the Oros therapeutic system (Alza Corp.), in which the antibodies and antigen binding fragments thereof are encapsulated in a semipermeable membrane that allows water to enter and push the drug out through a single small opening due to osmosis.
[0286] Controlled release polymer devices can be made for long-term systemic release after implantation of polymer devices (rods, columns, films, discs) or injections (microparticles). Matrix can be a form of microparticles such as microspheres, wherein reagents are dispersed in solid polymer matrix or microcapsules, wherein the material of the core is different from the material of the polymer shell, and peptides are dispersed or suspended in the core, which can be liquid or solid in nature. Unless specifically defined herein, microparticles, microspheres and microcapsules are interchangeable. Alternatively, polymers can be cast into flakes or films (ranging from nanometers to four centimeters), can be powders produced by grinding or other standard techniques, can even be gels, such as hydrogels.
[0287] Non-biodegradable or biodegradable matrices can be used for delivering fusion polypeptides or nucleic acids encoding fusion polypeptides, but biodegradable matrices are preferred in some embodiments. These can be natural or synthetic polymers, but synthetic polymers are preferred in some embodiments due to better characterization of degradation and release characteristics. Polymers are selected based on the time period over which they need to be released. In some cases, linear release may be the most useful, but in other cases, pulsed release or "batch release" can provide more effective results. Polymers can be in the form of hydrogels (usually absorbing up to about 90% by weight of water), and can be optionally cross-linked with multivalent ions or polymers.
[0288] These matrices can be formed by solvent evaporation, spray drying, solvent extraction and other methods well known to the skilled person. Biodigestible microspheres can be prepared using any method developed for preparing drug delivery microspheres, for example, as Mathiowitz and Langer, J.Controlled Release, Vol. 5, pp. 13-22 (1987); Mathiowitz et al., Reactive Polymers, Vol. 6, pp. 275-283 (1987); and Mathiowitz et al., J.Appl.PolymerSci., Vol. 35, described in pp. 755-774 (1988).
[0289] These devices can be formulated to release locally to treat the area of implantation or injection (usually providing a much smaller dose than would be required for systemic treatment) or for systemic delivery. These can be implanted or injected subcutaneously into muscle, fat, or swallowed.
[0290] III. Manufacturing Method
[0291] A. Methods for preparing antibodies
[0292] The disclosed antibodies can be produced in cell culture, in phage, or in various animals, including but not limited to cows, rabbits, goats, mice, rats, hamsters, guinea pigs, sheep, dogs, cats, monkeys, chimpanzees, and apes. In one embodiment, the various animals can be transgenic animals that have been genetically engineered to produce human or humanized antibodies. Therefore, in one embodiment, the antibodies are mammalian antibodies. Phage technology can be used to isolate initial antibodies or to produce variants with altered specificity or affinity characteristics. Such techniques are routine and well known in the art. In one embodiment, antibodies are produced by recombinant methods known in the art. For example, recombinant antibodies can be produced by transfecting host cells with a vector containing a DNA sequence encoding the antibody. One or more vectors can be used to transfect a DNA sequence that expresses at least one VL and one VH region in a host cell. Exemplary descriptions of recombinant methods for antibody generation and production include Delves, AntibodyProduction:EssentialTechniques (Wiley, 1997); Shephard et al. Monoclonal Antibodies (Oxford University Press, 2000); Goding, Monoclonal Antibodies: PrinciplesAndPractice (Academic Press, 1993); Current Protocols In Immunology (John Wiley & Sons, latest edition).
[0293] The disclosed antibodies can be modified by recombinant means to increase the greater efficacy of the antibodies in mediating the desired function. Therefore, it is also within the scope of the present invention that antibodies can be modified by substitution using recombinant means. Typically, the substitution is a conservative substitution. For example, at least one amino acid in the constant region of an antibody can be replaced with a different residue. See, for example, U.S. Pat. No. 5,624,821, U.S. Pat. No. 6,194,551, application WO 9958572; and Angal et al., Mol. Immunol., Vol. 30, pp. 105-108 (1993). Amino acid modifications include deletions, additions and substitutions of amino acids. In some cases, such changes are made to reduce undesirable activities, such as complement-dependent cytotoxicity. Typically, antibodies are labeled with a substance that provides a detectable signal by covalent or non-covalent attachment. A variety of labeling and conjugation techniques are known and widely reported in the scientific and patent literature. These antibodies can be screened for binding to proteins and polypeptides. See, for example Antibody Engineering:A Practical Approach (Oxford University Press, 1996).
[0294] For example, suitable antibodies with desired biological activity can be identified using in vitro assays, including but not limited to: proliferation, migration, adhesion, soft agar growth, angiogenesis, cell-to-cell communication, apoptosis, transport, signal transduction, and in vivo assays (such as inhibition of tumor growth). The antibodies provided herein can also be used for diagnostic applications. As capture or non-neutralizing antibodies, they can be screened for their ability to bind to a specific antigen without inhibiting receptor binding or biological activity of the antigen. As neutralizing antibodies, the antibodies can be used in competitive binding assays.
[0295] Antibodies that can be used in the disclosed compositions and methods include any class of complete immunoglobulins (i.e., complete antibodies), fragments thereof, and synthetic proteins comprising at least the antigen-binding variable domains of antibodies. The variable domain sequences differ between antibodies and are used for the binding and specificity of each specific antibody to its specific antigen. However, variability is usually not evenly distributed in the variable domains of antibodies. It is usually concentrated in three segments called complementary determining regions (CDRs) or hypervariable regions in the light and heavy chain variable domains. The more highly conserved parts of the variable domains are called frameworks (FRs). The variable domains of natural heavy and light chains each contain four FR regions that are primarily in a β-folded configuration and connected by three CDRs, which form loops that connect and form a part of the β-folded structure in some cases. The CDRs in each chain are held together in close proximity by the FR regions and contribute to the formation of the antigen binding site of the antibody together with the CDRs from the other chain.
[0296] Also disclosed are fragments of biologically active antibodies. These fragments, whether or not linked to other sequences, include insertions, deletions, substitutions or other selected modifications of specific regions or specific amino acid residues, provided that the activity of the fragment is not significantly altered or impaired compared to the unmodified antibody or antibody fragment.
[0297] Technology can also be applied to produce single-chain antibodies based on disclosed antibodies and antigen-binding fragments thereof. The method of producing single-chain antibodies is well known to those skilled in the art. By using a short peptide linker, the variable domains of heavy chain and light chain are fused together, thereby rebuilding the antigen binding site on a single molecule, a single-chain antibody can be formed. Without significantly destroying antigen binding or binding specificity, single-chain antibody variable fragments (scFv) have been developed, in which the C-terminus of one variable domain is connected to the N-terminus of another variable domain via 15 to 25 amino acid peptides or linkers. Select the linker to allow the heavy chain and light chain to be combined with their appropriate conformational orientation.
[0298] One embodiment provides a divalent single-chain variable fragment (di-scFv) that can be engineered by connecting two scFv. This can be accomplished by producing a single peptide chain with two VH regions and two VL regions, thereby producing a series of scFv. ScFv can also be designed to have a linker peptide that is too short for the two variable regions to fold together (about five amino acids), thereby forcing the scFv dimerization. This type is referred to as a double antibody. Double antibodies have been shown to have a dissociation constant up to 40 times lower than that of corresponding scFv, which means that they have a much higher affinity to their target. Still shorter joints (one or two amino acids) lead to the formation of trimers (three antibodies). Four antibodies have also been produced. Their affinity to their target is even higher than double antibodies.
[0299] Another embodiment provides monoclonal antibodies obtained from a substantially homogeneous population of antibodies, i.e., the individual antibodies within the population are identical except for possible naturally occurring mutations that may be present in a small subset of the antibody molecules. Monoclonal antibodies include "chimeric" antibodies, in which a portion of the heavy and / or light chain is identical or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the one or more chains is identical or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, as long as they exhibit the desired antagonistic activity.
[0300] Monoclonal antibodies can be prepared using any procedure that produces monoclonal antibodies. In the hybridoma method, mice or other suitable host animals are usually immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that specifically bind to the immunizing agent. Alternatively, lymphocytes can be immunized in vitro.
[0301] The disclosed antibodies can also be prepared by recombinant DNA methods. The DNA encoding the disclosed antibodies can be easily separated and sequenced using conventional methods (e.g., by using oligonucleotide probes that can specifically bind to the genes encoding mouse antibody heavy and light chains). Phage display technology can also be used to produce and screen libraries of antibodies or active antibody fragments.
[0302] Methods for preparing antibodies using protein chemistry are also known in the art. A method for producing a protein comprising an antibody is to connect two or more peptides or polypeptides together by protein chemistry techniques. For example, peptides or polypeptides can be chemically synthesized using currently available laboratory equipment using Fmoc (9-fluorenylmethoxycarbonyl) or Boc (tert-butyloxycarbonyl) chemistry. (Applied Biosystems, Inc., Foster City, CA). Those skilled in the art can easily understand that, for example, peptides or polypeptides corresponding to antibodies can be synthesized by standard chemical reactions. For example, a peptide or polypeptide can be synthesized and not cleaved from its synthetic resin, while another fragment of the antibody can be synthesized and then cleaved from the resin, thereby exposing the terminal groups blocked by function on the other fragment. Through a peptide condensation reaction, the two fragments can be covalently linked by a peptide bond at their carboxyl and amino termini, respectively, to form an antibody or its fragment. Alternatively, the peptide or polypeptide is independently synthesized in vivo as described above. Once separated, these independent peptides or polypeptides can be connected via similar peptide condensation reactions to form an antibody or its antigen-binding fragment.
[0303] For example, enzymatic ligation of cloned or synthetic peptide segments allows relatively short peptide fragments to be linked to produce larger peptide fragments, polypeptides or complete protein domains. Alternatively, native chemical ligation of synthetic peptides can be used to synthetically construct large peptides or polypeptides from shorter peptide fragments. The method consists of a two-step chemical reaction. The first step is the chemoselective reaction of an unprotected synthetic peptide-α-thioester with another unprotected peptide segment containing an amino-terminal Cys residue to obtain a thioester-linked intermediate as the initial covalent product. Without changing the reaction conditions, the intermediate undergoes a spontaneous, rapid intramolecular reaction to form a native peptide bond at the ligation site.
[0304] B. Methods of Preparing Isolated Nucleic Acid Molecules
[0305] One embodiment provides a nucleic acid encoding the disclosed antibody or antigen-binding fragment thereof. The nucleic acid may encode the entire antibody or antigen-binding fragment thereof or a light chain, a heavy chain, a combination thereof, or a CDR thereof.
[0306] Isolated nucleic acid molecules can be produced by standard techniques, including but not limited to ordinary molecular cloning and chemical nucleic acid synthesis techniques. For example, polymerase chain reaction (PCR) technology can be used to obtain isolated nucleic acids encoding variant polypeptides. PCR is a technique in which a target nucleic acid is enzymatically amplified. Typically, sequence information from the end of the region of interest or beyond can be used to design oligonucleotide primers that are identical in sequence to the opposite strand of the template to be amplified. PCR can be used to amplify specific sequences from DNA as well as RNA, including sequences from total genomic DNA or total cellular RNA. Primers are typically 14 to 40 nucleotides in length, but can range in length from 10 nucleotides to hundreds of nucleotides. Conventional PCR techniques are used, for example, in PCR Primer: A Laboratory Manual , Dieffenbach and Dveksler, eds., Cold Spring Harbor Laboratory Press, 1995. When RNA is used as a template source, a reverse transcriptase can be used to synthesize a complementary DNA (cDNA) strand. Ligase chain reaction, strand displacement amplification, self-sustaining sequence replication, or nucleic acid sequence-based amplification can also be used to obtain isolated nucleic acids. See, for example, Lewis (1992) Genetic Engineering News, Vol. 12, p. 1; Guatelli et al. (1990) Proc. Natl. Acad. Sci. USA, Vol. 87, pp. 1874-1878; and Weiss (1991) Science, Vol. 254, pp. 1292-1293.
[0307] The isolated nucleic acid can be chemically synthesized as a single nucleic acid molecule or a series of oligonucleotides (e.g., automated DNA synthesis in the 3' to 5' direction using the phosphoramidite technique). For example, one or more pairs of long oligonucleotides (e.g., >100 nucleotides) containing the desired sequence can be synthesized, wherein each pair contains complementary short segments (e.g., about 15 nucleotides) such that a duplex is formed when the oligonucleotide pairs are annealed. DNA polymerase can be used to extend the oligonucleotides, thereby producing a single double-stranded nucleic acid molecule per oligonucleotide pair, which can then be ligated into a vector. Isolated nucleic acids can also be obtained by mutagenesis. Nucleic acids encoding proteins can be mutated using standard techniques, including oligonucleotide-directed mutagenesis and / or site-directed mutagenesis by PCR. See, Short Protocols in Molecular Biology , Chapter 8, Green Publishing Associates and John Wiley & Sons, eds. Ausubel et al., 1992.
[0308] IV. How to use
[0309] The disclosed antibodies and antigen-binding fragments thereof can be used to modulate immune responses in subjects in need thereof. One embodiment provides a method of activating immune cells (e.g., T cells) expressing PD-1 by administering the disclosed antibodies and antigen-binding fragments thereof (optionally including a second therapeutic agent) to proliferate or enhance the biological activity of immune cells expressing PD-1.
[0310] A. Stimulation of immune response
[0311] 1. Treatment strategy
[0312] A method for inducing or enhancing an immune response in a subject is provided. Generally, the method comprises administering to the subject an effective amount of one or more of the disclosed antibodies and antigen-binding fragments thereof to immunospecifically bind to PD-1 and induce, promote or enhance stimulation or activation signals through PD-1 to activate immune cells. The immune response may be, for example, inducing, promoting or enhancing T cell activation, secretion of cytokines by immune cells, and T cell proliferation. An effective amount of the disclosed antibodies or antigen-binding fragments thereof may be administered to a subject in need thereof to overcome T cell exhaustion and / or T cell anergy. Overcoming T cell exhaustion or T cell anergy may be determined by measuring T cell function using known techniques.
[0313] These methods can be used in vivo or in vitro to induce, promote or enhance a stimulatory immune response.
[0314] In some embodiments, the antibody or its antigen binding fragment or the nucleic acid encoding the antibody or its antigen binding fragment is directly administered to the subject. In some embodiments, the antibody or its antigen binding fragment is contacted with a cell (e.g., an immune cell) in vitro, and the treated cell is administered to the subject (e.g., adoptive transfer). The antibody or its antigen binding fragment can make a stronger immune response possible. The disclosed composition can be used to stimulate or enhance an immune response involving T cells, thereby causing an activation signal through PD-1 on immune cells.
[0315] 2. Subjects to be treated
[0316] a. Cancer treatment
[0317] The disclosed antibodies and compositions and methods thereof can be used to treat cancer. Generally, by administering to a subject a certain amount of the disclosed antibodies or antigen-binding fragments thereof that induce, promote or enhance activation signals through PD-1, the agent is used to stimulate or enhance the subject's immune response to cancer. The method can alleviate one or more symptoms of cancer.
[0318] Immune cells activated by the disclosed antibodies or fragments thereof can kill cancer cells and reduce the tumor burden of the subject. The term "cancer cell" is intended to cover precancerous cells and malignant cancer cells. In some embodiments, cancer refers to a benign tumor that remains localized. In other embodiments, cancer refers to a malignant tumor that has invaded and destroyed adjacent body structures and spread to distal sites. In other embodiments, cancer is associated with specific cancer antigens (e.g., pan-cancer antigens (KS1 / 4), ovarian cancer antigens (CA125), prostate-specific antigens (PSA), carcinoembryonic antigens (CEA), CD19, CD20, HER2 / neu, etc.).
[0319] The methods and antibody compositions disclosed herein can be used to treat or prevent a variety of cancers or other abnormal proliferative diseases, including, but not limited to, the following: cancers, including bladder cancer, breast cancer, colon cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, stomach cancer, cervical cancer, thyroid cancer, and skin cancer; including squamous cell carcinoma; lymphoid hematopoietic tumors, including leukemias, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, and Berkett's lymphoma; myeloid hematopoietic tumors, including leukemias, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, and Berkett's lymphoma; Tumors, including acute and chronic myeloid and promyelocytic leukemias; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; other tumors, including melanoma, seminoma, teratoma, neuroblastoma, and glioma; tumors of the central and peripheral nervous system, including astrocytoma, neuroblastoma, glioma, and schwannoma; tumors of mesenchymal origin, including fibrosarcoma, rhabdomyosarcoma, and osteosarcoma; and other tumors, including melanoma, xenoderma pegmentosum, keratoactanthoma, seminoma, follicular thyroid carcinoma, and teratoma.
[0320] Cancers caused by abnormal apoptosis can also be treated by the disclosed methods and compositions. Such cancers may include, but are not limited to, follicular lymphoma, cancers with p53 mutations, hormone-dependent tumors of the breast, prostate, and ovary, and precancerous lesions such as familial adenomatous polyposis and myelodysplastic syndrome. In specific embodiments, malignant or dysplastic changes (e.g., metaplasia and atypical hyperplasia) or hyperproliferative diseases in the ovary, bladder, breast, colon, lung, skin, pancreas, or uterus are treated or prevented by the methods and compositions. In other specific embodiments, sarcomas, melanomas, or leukemias are treated or prevented by the methods and compositions.
[0321] Specific cancers and related diseases that can be treated or prevented by the methods and compositions disclosed herein include, but are not limited to: leukemias, including, but not limited to, acute leukemias, acute lymphocytic leukemias, acute myeloid leukemias (such as myeloblastic leukemia, promyelocytic leukemia, myelomonocytic leukemia), monocytic leukemias, erythroid leukemias, and myelodysplastic syndromes, chronic leukemias such as, but not limited to, chronic myeloid (granulocytic) leukemia, chronic lymphocytic leukemia, hairy cell leukemia; polycythemia vera; lymphomas, such as, but not limited to, Hodgkin's disease or non-Hodgkin's disease lymphomas (e.g., diffuse anaplastic lymphoma kinase (ALK) negative, large B-cell lymphoma (DLBCL); diffuse anaplastic lymphoma kinase (ALK) positive, large B-cell lymphoma (DLBCL); anaplastic lymphoma kinase (ALK) positive, ALK+ anaplastic large cell lymphoma (ALCL), acute myeloid lymphoma (AML); multiple myeloma, such as but not limited to smoldering multiple myeloma, non-secretory myeloma, osteosclerotic myeloma, plasma cell leukemia, solitary plasmacytoma and extramedullary plasmacytoma; Waldenstrom's macroglobulinemia; monoclonal gammopathy of undetermined significance; benign monoclonal gammopathy; heavy chain disease; bone and connective tissue sarcomas, such as but not limited to osteosarcoma, osteogenic sarcoma, chondrosarcoma, Ewing's sarcoma, malignant giant cell tumor, fibrosarcoma of bone, chordoma, periosteal sarcoma, soft tissue sarcoma, angiosarcoma (angioendothelioma), fibrosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, schwannoma, rhabdomyosarcoma, synovial sarcoma; brain tumors, including but not limited to glioma, astrocytoma, brain stem glioma, ependymoma, oligodendroglioma, non-neural glioma, acoustic neuroma, craniopharyngioma, medulloblastoma, meningioma, pineal cell tumor, pineoblastoma, primary brain lymphoma; breast cancer, including but not limited to adenocarcinoma, lobular (small cell) carcinoma, intraductal carcinoma, medullary breast cancer, mucinous breast cancer, tubular breast cancer, papillary breast cancer, Paget's disease and inflammatory breast cancer; adrenal cancer, including but not limited to pheochromocytoma and adrenocortical carcinoma; thyroid cancers, such as, but not limited to, papillary or follicular thyroid cancer, medullary thyroid cancer, and anaplastic thyroid cancer; pancreatic cancer, including, but not limited to, insulinomas, gastrinomas, glucagonomas, vasodilatory peptide tumors, somatostatin-secreting tumors, and carcinoid or islet cell tumors; pituitary cancers, including, but not limited to, Cushing's disease, prolactin-secreting tumors, acromegaly, and diabetes insipidus; eye cancers, including, but not limited to, eye melanomas, such as iris melanoma, choroidal melanoma, and ciliary body melanoma and retinoblastoma; vaginal cancers, including, but not limited to, squamous cell carcinoma, adenocarcinoma, and melanoma; vulvar cancers, including, but not limited to, squamous cell carcinoma, melanoma, adenocarcinoma, basal cell carcinoma, sarcoma, and Paget's disease; cervical cancers, including, but not limited to, squamous cell carcinoma and adenocarcinoma;Uterine cancer, including but not limited to endometrial cancer and uterine sarcoma; ovarian cancer, including but not limited to ovarian epithelial cancer, borderline tumors, germ cell tumors and stromal tumors; esophageal cancer, including but not limited to squamous carcinoma, adenocarcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, adenosquamous carcinoma, sarcoma, melanoma, plasmacytoma, verrucous carcinoma and oat cell (small cell) carcinoma; gastric cancer, including but not limited to adenocarcinoma, mycosis fungoides (polypoid) carcinoma, ulcer carcinoma, superficial spreading carcinoma, diffuse spreading carcinoma, malignant lymphoma, liposarcoma, fibrosarcoma and carcinosarcoma; colon cancer; rectal cancer; liver cancer, including but not limited to hepatocellular carcinoma and hepatoblastoma; gallbladder cancer, including but not limited to adenocarcinoma; bile duct cancer, including but not limited to papillary carcinoma, nodular carcinoma and diffuse carcinoma; lung cancer, including but not limited to non-small cell lung cancer, squamous cell carcinoma (epidermoid carcinoma), adenocarcinoma, large cell carcinoma and small cell lung cancer; testicular cancer, including but not limited to genital tumors the ovarian cancer, including but not limited to ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, In addition, cancer includes myxosarcoma, osteogenic sarcoma, endotheliosarcoma, lymphangioendotheliosarcoma, mesothelioma, synovioma, hemangioblastoma, epithelial carcinoma, cystadenocarcinoma, bronchogenic carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma and papillary adenocarcinoma (for a review of such diseases, see Fishman et al., 1985, Medicine, 2nd Edition, JB Lippincott Co., Philadelphia and Murphy et al., 1997, "Informed Decisions: The Complete Book of Cancer Diagnosis, Treatment, and Recovery", Viking Penguin, Penguin Books U.S.A., Inc., United States of America). ;
[0322] b. Treatment of infection
[0323] The disclosed antibody compositions and methods can be used to treat infections and infectious diseases. Generally, by administering to a subject a certain amount of one or more of the disclosed antibodies or antigen-binding fragments thereof that send activation or stimulation signals through PD-1, the agent is used to stimulate or enhance the subject's immune response to the infection. The method can alleviate one or more symptoms of the infection.
[0324] Infection or disease can be caused by bacteria, viruses, protozoa, helminths or other microbial pathogens that enter cells and are attacked, ie, by cytotoxic T lymphocytes.
[0325] Infection or disease can be acute or chronic. Acute infection is usually a short-term infection. During acute microbial infection, immune cells begin to express immunomodulatory receptors. Therefore, in some embodiments, the method includes increasing the immune stimulation response to acute infection.
[0326] The infection may be caused by, for example, but not limited to, Candida albicans, Listeria monocytogenes, Streptococcus pyogenes, Streptococcus pneumoniae, Neisseria meningitidis, Staphylococcus aureus, Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa, or Mycobacterium.
[0327] In some embodiments, the disclosed antibody compositions are used to treat chronic infections, e.g., infections in which T cell exhaustion or T cell anergy has occurred, resulting in the infection being maintained in the host for an extended period of time.
[0328] Exemplary infections to be treated are chronic infections caused by hepatitis viruses, human immunodeficiency virus (HIV), human T-lymphotrophic virus (HTLV), herpes virus, Epstein-Barr virus, or human papillomavirus.
[0329] Because viral infections are primarily cleared by T cells, increasing T cell activity would be therapeutically useful in cases where faster or complete clearance of infectious viral agents is beneficial to animals or human subjects. Thus, the disclosed compositions can be administered for the treatment of local or systemic viral infections, including but not limited to immunodeficiency (e.g., HIV), papilloma (e.g., HPV), herpes (e.g., HSV), encephalitis, influenza (e.g., human influenza virus A) and the common cold (e.g., human rhinovirus) and other viral infections caused by, for example, HTLV, hepatitis viruses, respiratory syncytial viruses, vaccinia viruses, and rabies viruses. The molecule can be administered topically to treat viral skin diseases, such as herpes lesions or herpes zoster or genital warts. The molecule can also be administered systemically to treat systemic viral diseases, including but not limited to AIDS, influenza, the common cold, or encephalitis.
[0330] Representative infections that can be treated include, but are not limited to, infections caused by microorganisms including, but are not limited to, Actinomyces, Anabaena, Bacillus, Bacteroides, Bdellovibrio, Bordetella, Borrelia, Campylobacter, Caulobacter, Chlamydia, Chlorobium, Chromatium, Clostridium, Corynebacterium, Cytophaga, Deinococcus, Escherichia, Francisella, Halobacterium, Heliobacter, Haemophilus, Hemophilus influenzae type b.influenza (HIB), Hyphomicrobium, Legionella, Leptspirosis, Listeria, Meningococcus A, B, and C, Methanobacterium, Micrococcus, Myobacterium, Mycoplasma, Myxococcus, Neisseria, Nitrobacter, Oscillatoria, Prochloron, Proteus, Pseudomonas, Phodospirillum, Rickettsia, Salmonella, Shigella, Spirillum, Spirochaeta, Staphylococcus, Streptococcus, Streptomyces, Sulfolobus, Thermoplasma, Thiobacillus, Treponema, Vibrio, Yersinia, Cryptococcus neoformans neoformans), Histoplasma capsulatum, Candida albicans, Candida tropicalis, Nocardia asteroides, Rickettsia ricketsii, Rickettsia typhi, Mycoplasma pneumoniae, Chlamydial psittaci, Chlamydial trachomatis, Plasmodium falciparum, Trypanosoma brucei, Entamoeba histolytica, Toxoplasma gondiigondii), Trichomonas vaginalis, and Schistosoma mansoni.
[0331] Other microorganisms that can be treated using the disclosed compositions and methods include bacteria such as those of the genera Klebsiella, Serratia, Pasteurella; pathogens associated with cholera, tetanus, botulism, anthrax, plague, and Lyme disease; or fungal or parasitic pathogens such as Candida (albicans, krusei, glabrata, tropicalis, etc.), Cryptococcus, Aspergillus (fumigatus, niger, etc.), Mucor (Genus Mucorales (mucor, absidia, rhizophus), Sporothrix (schenkii), Blastomyces (dermatitidis), Paracoccidioides (brasiliensis), Coccidioides (immitis), and Histoplasma (capsulatuma), Entamoeba, histolytica, Balantidium coli, Naegleria fowleri, Acanthamoeba, Giardia lambia, Cryptosporidium sp.), Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Toxoplasma gondi, etc.), Sporothrix, Blastomyces, Paracoccidioides, Coccidioides, Histoplasma, Entamoeba, histolytica, Balantidium, Naegleria, Acanthamoeba, Giardia, Cryptosporidium, Pneumocystis, Plasmodium, Babesia or Trypanosoma, etc.
[0332] V. Combination Therapies for Enhancing Immune Responses
[0333] The disclosed antibodies, antigen-binding fragments thereof, and compositions thereof can be administered to a subject in need thereof alone or in combination with one or more additional therapeutic agents. In some embodiments, the antibody, antigen-binding fragment thereof, and additional therapeutic agent are administered separately but simultaneously. The antibody, antigen-binding fragment thereof, and additional therapeutic agent can also be administered as part of the same composition. In other embodiments, the antibody, antigen-binding fragment thereof, and second therapeutic agent are administered separately and at different times but as part of the same treatment regimen. Additional therapeutic agents can be administered before, after, or alternately with the administration of the disclosed antibodies, antigen-binding fragment thereof.
[0334] The first therapeutic agent may be administered to the subject 1, 2, 3, 4, 5, 6 or more hours, or 1, 2, 3, 4, 5, 6, 7 or more days prior to administration of the second therapeutic agent. In some embodiments, one or more doses of the first agent may be administered to the subject every 1, 2, 3, 4, 5, 6, 7, 14, 21, 28, 35 or 48 days prior to the first administration of the second agent. The antibody and antigen-binding fragment thereof may be the first therapeutic agent or the second therapeutic agent.
[0335] The antibodies and antigen-binding fragments thereof and the additional therapeutic agent can be administered as part of a treatment regimen. For example, if the first therapeutic agent can be administered to the subject every four days, the second therapeutic agent can be administered on the first, second, third, or fourth day, or a combination thereof. The first therapeutic agent or the second therapeutic agent can be administered repeatedly throughout the treatment regimen.
[0336] Exemplary additional therapeutic agents include, but are not limited to, cytokines, chemotherapeutic agents, radionuclides, other immunotherapeutic agents, enzymes, antibiotics, antiviral agents (particularly protease inhibitors alone or in combination with nucleosides for the treatment of HIV or hepatitis B or C), antiparasitics (helminths, protozoa), growth factors, growth inhibitors, hormones, hormone antagonists, antibodies and biologically active fragments thereof (including humanized, single chain and chimeric antibodies), antigens and vaccine formulations (including adjuvants), peptide drugs, anti-inflammatory agents, ligands that bind to Toll-like receptors (including but not limited to CpG oligonucleotides) to activate the innate immune system, molecules that mobilize and optimize the adaptive immune system, other molecules that activate or upregulate the action of cytotoxic T lymphocytes, natural killer cells and helper T cells, and other molecules that inactivate or downregulate inhibitory or regulatory T cells.
[0337] The additional therapeutic agent is selected according to the condition, disorder or disease to be treated.For example, an immunomodulatory agent may be co-administered with one or more additional agents that function to enhance or promote an immune response or to reduce or inhibit an immune response.
[0338] A. Antimicrobial Agents
[0339] In one embodiment, the antibodies and antigen-binding fragments thereof can be administered to a subject in combination with an antimicrobial agent such as an antibiotic, an antifungal agent, an antiviral agent, an antiparasitic agent, or an essential oil. In another embodiment, the disclosed antibodies and antigen-binding fragments thereof can be used in a preventive or prophylactic role in the treatment and prevention of disease and in the context of severe traumatic injuries such as extensive burns, open fractures, accidental amputations, or other wounds.
[0340] In some embodiments, antibodies and antigen-binding fragments thereof and / or antimicrobial agents are administered to subjects upon admission to the hospital to prevent further bacterial, fungal or viral complications. Antibiotics can target pathogens, and antibodies and antigen-binding fragments thereof can stimulate the immune system to provide an enhanced response to treat or prevent further infection or disease.
[0341] 1. Chemotherapeutic agents
[0342] Antibodies and antigen-binding fragments thereof can be combined with one or more chemotherapeutic agents and pro-apoptotic agents. Representative chemotherapeutic agents include, but are not limited to, amsacrine, bleomycin, busulfan, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clofarabine, crisantaspase, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, docetaxel, doxorubicin, epirubicin, etoposide, fludarabine, fluorouracil, gemcitabine, hydroxyurea, idarubicin, ifosfamide, idarubicin ... The invention relates to apoptosis-promoting agents, for example, irinotecan, leucovorin, liposomal doxorubicin, liposomal daunorubicin, lomustine, melphalan, mercaptopurine, mesna, methotrexate, mitomycin, mitoxantrone, oxaliplatin, paclitaxel, pemetrexed, pentostatin, procarbazine, raltitrexed, satraplatin, streptozotocin, tegafururacil, temozolomide, teniposide, thiotepa, thioguanine, topotecan, thiosulfan, vinblastine, vincristine, vindesine, vinorelbine, or a combination thereof. Representative pro-apoptotic agents include, but are not limited to, fludarabine taurosporine, cycloheximide, actinomycin D, lactosylceramide, 15d-PGJ (2), and a combination thereof.
[0343] 2. Other immunomodulators
[0344] a. PD-1 antagonists
[0345] In some embodiments, antibodies and antigen-binding fragments thereof are co-administered with PD-1 antagonists. Programmed death 1 (PD-1) is a member of the CD28 receptor family that produces a negative immune response when induced on T cells. Contact between PD-1 and one of its ligands (B7-H1 or B7-DC) induces an inhibitory response that reduces the intensity and / or duration of T cell proliferation and / or T cell responses. Suitable PD-1 antagonists are described in U.S. Patents 8,114,845, 8,609,089, and 8,709,416 (all of which are expressly incorporated herein by reference in their entirety), and include compounds or agents that bind to and block PD-1 ligands to interfere with or inhibit ligand binding to PD-1 receptors, or directly bind to and block PD-1 receptors without inducing inhibitory signaling through PD-1 receptors.
[0346] In some embodiments, the PD-1 receptor antagonist directly binds to the PD-1 receptor without triggering inhibitory signaling, and also binds to the ligand of the PD-1 receptor to reduce or inhibit the ligand from triggering signaling through the PD-1 receptor. By reducing the number and / or amount of ligands that bind to the PD-1 receptor and trigger inhibitory signaling, fewer cells are attenuated by the negative signals delivered by PD-1 signaling, and a stronger immune response can be achieved.
[0347] It is believed that PD-1 signaling is driven by binding to PD-1 ligands (such as B7-H1 or B7-DC), which are in close proximity to peptide antigens presented by the major histocompatibility complex (MHC) (see, e.g., Freeman, Proc. Natl. Acad. Sci. USA, Vol. 105, pp. 10275-10276 (2008)). Therefore, proteins, antibodies or small molecules that prevent PD-1 and TCR from being co-attached on the T cell membrane are also useful PD-1 antagonists.
[0348] In some embodiments, the PD-1 receptor antagonist is a small molecule antagonist or antibody that reduces or interferes with PD-1 receptor signaling by binding to a ligand of PD-1 or to PD-1 itself, particularly where co-ligation of PD-1 with the TCR is not followed by such binding, thereby not triggering inhibitory signaling through the PD-1 receptor.
[0349] Other PD-1 antagonists contemplated by the methods of the present invention include antibodies that bind to PD-1 or ligands of PD-1, as well as other antibodies.
[0350] Suitable anti-PD-1 antibodies include, but are not limited to, those described in the following U.S. Patent Nos. 7332582, 7488802, 7521051, 7524498, 7563869, 7981416, 8088905, 8287856, 8580247, 8728474, 8779105, 9067999, 9073994, 9084776, 9205148, 9358289, 9387247, 9492539, 9492540, all of which are incorporated herein by reference in their entirety.
[0351] See also Berger et al., Clin. Cancer Res., Vol. 14, p. 30443051 (2008).
[0352] Exemplary anti-PD-L1 antibodies include, but are not limited to, those described in the following U.S. Patent Nos.: 8383796, 9102725, 9273135, 9393301, and 9580507, all of which are expressly incorporated herein by reference in their entirety.
[0353] For anti-B7-DC (also known as anti-PD-L2) antibodies, see U.S. Patent Nos.: 7,411,051, 7,052,694, 7,390,888, 8188238, and 9255147.
[0354] Other exemplary PD-1 receptor antagonists include, but are not limited to, PD-L2 polypeptides (including homologs and variants thereof) and any of the aforementioned active fragments and fusion proteins incorporating any of these. In some embodiments, the fusion protein includes a soluble portion of B7-DC coupled to the Fc portion of an antibody (such as human IgG) and does not include all or part of the transmembrane portion of human B7-DC.
[0355] The PD-1 antagonist may also be a fragment of mammalian PD-L1, such as a fragment from a mouse or primate such as a human, wherein the fragment binds to and blocks PD-1 but does not cause inhibitory signaling through PD-1. The fragment may also be part of a fusion protein (e.g., an Ig fusion protein).
[0356] Other useful polypeptide PD-1 antagonists include those that bind to the ligand of the PD-1 receptor. These include PD-1 receptor protein or its soluble fragments, which can bind to PD-1 ligands (such as PD-L1 or B7-DC) and prevent binding to endogenous PD-1 receptors, thereby preventing inhibitory signaling. It has also been shown that PD-L1 binds to protein B7.1 (Butte et al., Immunity, Vol. 27, pp. 111-122 (2007)). Such fragments also include soluble ECD portions of PD-1 proteins, which include mutations such as A99L mutations that enhance binding to natural ligands (Molnar et al., PNAS, Vol. 105, pp. 10483-10488 (2008)). B7-1 or its soluble fragments that can bind to PD-L1 ligands and prevent binding to endogenous PD-1 receptors to prevent inhibitory signaling are also useful.
[0357] PD-1 and PD-L1 antisense nucleic acids (both DNA and RNA) and siRNA molecules can also be PD-1 antagonists. Such antisense molecules prevent the expression of PD-1 on T cells and the production of T cell ligands such as PD-L1 and / or PD-L2. For example, siRNA (e.g., about 21 nucleotides in length, which is specific to genes encoding PD-1 or encoding PD-1 ligands, and the oligonucleotides can be easily commercially available) (see Cubillos-Ruiz et al., J.Clin.Invest., Vol. 119, No. 8, pp. 2231-2244 (2009)) is easily taken up by cells expressing PD-1 and PD-1 ligands, and the expression of these receptors and ligands is reduced, so as to achieve a reduction in inhibitory signaling in T cells, thereby activating T cells.
[0358] b. CTLA4 antagonists
[0359] Other molecules for mediating the role of T cells in immune responses are also contemplated as additional therapeutic agents. In some embodiments, the molecule is an antagonist of CTLA4, such as an antagonist anti-CTLA4 antibody. Examples of anti-CTLA4 antibodies contemplated for use in the methods of the invention include antibodies as described in PCT / US2006 / 043690 (Fischkoff et al., WO / 2007 / 056539).
[0360] Dosages for anti-PD-1, anti-B7-H1, and anti-CTLA4 antibodies are known in the art and may be, for example, in the range of 0.1 to 100 mg / kg, or in a narrower range of 1 to 50 mg / kg or 10 to 20 mg / kg. Suitable doses for human subjects may be between 5 and 15 mg / kg, with 10 mg / kg of antibody (e.g., human anti-PD-1 antibody) being a specific embodiment.
[0361] Specific examples of anti-CTLA4 antibodies used in the methods of the present invention are Ipilimumab (a human anti-CTLA4 antibody) administered at a dose of, for example, about 10 mg / kg and Tremelimumab (a human anti-CTLA4 antibody) administered at a dose of, for example, about 15 mg / kg. See also Sammartino et al., Clinical Kidney Journal, Vol. 3, No. 2, pp. 135-137 (2010), published online in December 2009.
[0362] In other embodiments, the antagonist is a small molecule. A series of small organic compounds have been shown to bind to the B7-1 ligand to prevent binding to CTLA4 (see Erbe et al., J. Biol. Chem., Vol. 277, pp. 7363-7368 (2002)). Such small organics can be administered alone or in combination with anti-CTLA4 antibodies to reduce inhibitory signaling of T cells.
[0363] 3. Enhancer
[0364] In some embodiments, the additional therapeutic agent comprises an enhancer. The enhancer may act to increase the efficacy of the immune response upregulator by more than one mechanism, but the exact mechanism of action is not important to the broad practice of the invention.
[0365] In some embodiments, the enhancer is cyclophosphamide. or ) is an oxazaphosphorine drug, and analogs include ifosfamide (IFO, Ifex), perfosfamide, chloroethene cyclophosphamide (trofosfamide, Ixoten) and pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof (U.S. Patent Application 20070202077, the entirety of which is incorporated herein). Ifosfamide It is a structural analogue of cyclophosphamide, and its mechanism of action is considered to be the same or substantially similar to that of cyclophosphamide. Perphosphamide (4-peroxyhydroxycyclophosphamide) and chloroethene cyclophosphamide are also alkylating agents, which are structurally related to cyclophosphamide. For example, perphosphamide alkylates DNA, thereby inhibiting DNA replication and RNA and protein synthesis. New oxazaphosphorine heterocyclic cyclohexane derivatives have been designed and evaluated, attempting to improve selectivity and response while reducing host toxicity (Liang J, Huang M, Duan W, Yu XQ, Zhou S., " Design of new oxazaphosphorine anticancerdrugs. ", Curr Pharm Des., 2007, Vol. 13 No. 9, pp. 963-978, Review). These include mafosfamide (NSC 345842), glufosfamide (D19575, β-D-glucosyl isophosphamide mustard), S-(-)-bromoifosfamide (CBM-11), NSC 612567 (aldophosphamide perhydrothiazine) and NSC 613060 (aldophosphamide thiazolidine). Mafosfamide is an oxazaphosphorinane analog, a chemically stable 4-thioethanesulfonate salt of 4-hydroxy-CPA. Glufosfamide is an IFO derivative in which the alkylated metabolite of IFO, isophosphamide mustard, is linked to a β-D-glucose molecule via a glycosidic bond. Additional cyclophosphamide analogs are described in U.S. Pat. No. 5,190,929, entitled "Cyclophosphamide analogs useful as anti-tumoragents," which is incorporated herein by reference in its entirety.
[0366] Although CTX itself is non-toxic, some of its metabolites are cytotoxic alkylating agents that induce DNA crosslinking and cause strand breaks at higher doses. Many cells are resistant to CTX because they express high levels of the detoxifying enzyme aldehyde dehydrogenase (ALDH). CTX targets proliferating lymphocytes because lymphocytes (but not hematopoietic stem cells) express only low levels of ALDH, and circulating cells are most sensitive to DNA alkylating agents.
[0367] In one embodiment, low doses of CTX are used in combination with the disclosed antibodies and antigen-binding fragments thereof. Low doses of CTX (<200 mg / kg) may have immunostimulatory effects, including stimulating anti-tumor immune responses in human and mouse cancer models (Brode & Cooke Crit Rev. Immunol., Vol. 28, pp. 109-126 (2008)). These low doses are subtherapeutic and do not have direct anti-tumor activity. In contrast, high doses of CTX inhibit anti-tumor responses. Several mechanisms can explain the role of CTX in enhancing anti-tumor immune responses: (a) depletion of CD4+CD25+FoxP3+Treg (and specifically proliferated Treg, which may be particularly suppressive), (b) depletion of B lymphocytes; (c) induction of nitric oxide (NO), resulting in inhibition of tumor cell growth; (d) mobilization and amplification of CD11b+Gr-1+MDSC. These primary effects have many secondary effects; for example, macrophages produce more IFN-γ and less IL-10 after Treg depletion. CTX has also been shown to induce type I IFN expression and promote homeostatic proliferation of lymphocytes.
[0368] Treg depletion is most often cited as the mechanism by which CTX enhances antitumor immune responses. This conclusion is based in part on the results of adoptive transfer experiments. In the AB1-HA tumor model, CTX treatment gave a 75% cure rate on day 9. On day 12, the transfer of purified Tregs almost completely suppressed the CTX response (van der Most et al., Cancer Immunol. Immunother., Vol. 58, pp. 1219-1228 (2009)). Similar results were observed in the HHD2 tumor model: adoptive transfer of CD4+CD25+Tregs after CTX pretreatment eliminated the therapeutic response to the vaccine (Taieb, J., J. Immunol., Vol. 176, pp. 2722-2729 (2006)).
[0369] A large number of human clinical trials have demonstrated that low-dose CTX is a safe, well-tolerated, and effective agent for promoting anti-tumor immune responses (Bas, & Mastrangelo, Cancer Immunol. Immunother., Vol. 47, pp. 1-12 (1998)).
[0370] In one embodiment, the optimal dose of CTX to enhance anti-tumor immune responses is a dose that reduces total T cell counts by reducing Treg levels below the normal range but is subtherapeutic (see Machiels et al., Cancer Res., Vol. 61, pp. 3689-3697 (2001)).
[0371] In some embodiments, CTX is used as an immunopotentiator with a dosage of 300mg / m2. In another embodiment, for average males (6 feet, 170 pounds (78kg), body surface area is 1.98m2), 300mg / m2, the dosage of CTX is 8mg / kg or 624mg total protein. In cancer mouse models, efficacy is observed in a dosage range of 15-150mg / kg, which is related to the total protein of 0.45-4.5mg in 30g mice (Machiels et al., Cancer Res., Vol. 61, pp. 3689-3697 (2001); Hengst et al., Cancer Res., Vol. 41, pp. 2163-2167 (1981); Hengst, Cancer Res., Vol. 40, pp. 2135-2141 (1980)).
[0372] For larger mammals, such as primates (such as humans, patients), such mg / m2 doses may be used, but unit doses administered at limited time intervals may also be used. Such unit doses may be administered daily for a limited period of time, such as up to 3 days, up to 5 days, up to 7 days, up to 10 days, up to 15 days, or up to 20 days or up to 25 days, all of which are specifically contemplated by the present invention. The same regimen may be applied to the other enhancers described herein.
[0373] In other embodiments, the enhancing agent is a T-regulatory cell (T-reg)-lowering agent such as sunitinib. Anti-TGFβ or imatinib The treatment regimen may also include the administration of an adjuvant.
[0374] Useful enhancers also include mitotic inhibitors such as paclitaxel, aromatase inhibitors (e.g., letrozole) and angiogenesis inhibitors (VEGF inhibitors, e.g., Avastin, VEGF-Trap) (see, e.g., Li et al., "Vascular endothelial growth factor blockade reduces intratumoral regulatory T cellsand enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.", Clin Cancer Res., November 15, 2006, Vol. 12, No. 22, pp. 6808-6816), anthracyclines, oxaliplatin, doxorubicin, TLR4 antagonists, and IL-18 antagonists.
[0375] VI. Transgenic Animals
[0376] One embodiment provides a transgenic animal that produces an antibody or antigen-binding fragment thereof having a heavy chain CDR having an amino acid sequence according to SEQ ID NOs: 6, 7, and 8 and a light chain CDR having an amino acid sequence according to SEQ ID NOs: 12, 13, and 14. In one embodiment, the transgenic animal is a rodent, such as a mouse.
[0377] Another embodiment provides a transgenic animal that produces an antibody or antigen-binding fragment thereof having a heavy chain CDR having an amino acid sequence according to SEQ ID NOs: 18, 19, and 20 and three different light chain CDRs having an amino acid sequence selected from the group consisting of SEQ ID NOs: 24, 13, and 25. In one embodiment, the transgenic animal is a rodent, such as a mouse.
[0378] Another embodiment provides a transgenic animal that produces an antibody or antigen-binding fragment thereof having a heavy chain CDR having an amino acid sequence according to SEQ ID NOs: 29, 30, and 31 and a light chain CDR having an amino acid sequence according to SEQ ID NOs: 35, 36, and 37. In one embodiment, the transgenic animal is a rodent, such as a mouse.
[0379] Methods for preparing transgenic animals that produce antibodies are known in the art. See, for example, A. Jakobovits, Curr Opin Biotechnol., Vol. 6, No. 5, pp. 561-566, 1995 and Brüggemann, M. et al., Arch Immunol Ther Exp (Warsz)., Vol. 63, No. 2, pp. 101-108 (2015); Jakobovits, A. et al., "From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice.", Nat Biotechnol., Vol. 25, No. 10, pp. 1134-1143 (2007); Lonberg N. (2005), "Human antibodies from transgenic animals.", Nat Biotechnol., Vol. 23, No. 9, pp. 1117-1125, and U.S. Patents 9,708,635, 9,686,970, 9,499,838, 9,445,581, 9,388,446, 8,835,712, 8,703,485, 8,232,449, 7,795,494, and 5,939,598.
[0380] The embodiments of various aspects provided by the present invention are also described by any of the following paragraphs.
[0381] Embodiment 1. An antibody or antigen-binding fragment thereof comprising a heavy chain complementarity determining region (CDR) and a light chain CDR, wherein the heavy chain CDR has an amino acid sequence according to SEQ ID NOs: 6, 7 and 8, and the light chain CDR has an amino acid sequence according to SEQ ID NOs: 12, 13 and 14.
[0382] Embodiment 2. An antibody or antigen-binding fragment thereof according to Embodiment 1, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO: 4 or 5.
[0383] Embodiment 3. An antibody or antigen-binding fragment thereof according to Embodiment 1 or 2, comprising a light chain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO: 10 or 11.
[0384] Embodiment 4. An antibody or any antigen-binding fragment thereof comprising a heavy chain and a light chain, wherein the heavy chain has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity with SEQ ID NO: 4 or 5, and the light chain has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity with SEQ ID NO: 10 or 11.
[0385] Embodiment 5. A transgenic animal engineered to express the antibody or antigen-binding fragment thereof according to any one of Embodiments 1 to 4.
[0386] Embodiment 6. The transgenic animal of embodiment 5, wherein the animal is a rodent.
[0387] Embodiment 7. The transgenic animal of embodiment 6, wherein the rodent is a mouse.
[0388] Embodiment 8. A nucleic acid encoding a heavy chain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO:4 or 5.
[0389] Embodiment 9. A nucleic acid encoding a light chain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO: 10 or 11.
[0390] Embodiment 10. An antibody or antigen-binding fragment thereof comprising a heavy chain CDR and a light chain CDR, wherein the heavy chain CDR has an amino acid sequence according to SEQ ID NOs: 18, 19 and 20, and the light chain CDR has an amino acid sequence according to SEQ ID NOs: 24, 13 and 25.
[0391] Embodiment 11. An antibody or antigen-binding fragment thereof according to Embodiment 10, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO: 16 or 17.
[0392] Embodiment 12. An antibody or antigen-binding fragment thereof according to Embodiment 10 or 11, wherein the antibody or antigen-binding fragment thereof comprises a light chain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO: 22 or 23.
[0393] Embodiment 13. An antibody or antigen-binding fragment thereof comprising a heavy chain and a light chain, wherein the heavy chain has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity with SEQ ID NO: 16 or 17, and the light chain has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity with SEQ ID NO: 22 or 23.
[0394] Embodiment 14. A transgenic animal engineered to express the antibody or antigen-binding fragment thereof according to any one of Embodiments 10 to 13.
[0395] Embodiment 15. The transgenic animal of embodiment 14, wherein the animal is a rodent.
[0396] Embodiment 16. The transgenic animal of embodiment 15, wherein the rodent is a mouse.
[0397] Embodiment 17. A nucleic acid encoding a heavy chain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO: 16 or 17.
[0398] Embodiment 18. A nucleic acid encoding a light chain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO:22 or 23.
[0399] Embodiment 19. An antibody or antigen-binding fragment thereof comprising a heavy chain CDR and a light chain CDR, wherein the heavy chain CDR has an amino acid sequence according to SEQ ID NOs: 29, 30 and 31, and the light chain CDR has an amino acid sequence according to SEQ ID NOs: 35, 36 and 37.
[0400] Embodiment 20. An antibody or antigen-binding fragment thereof according to Embodiment 19, comprising a heavy chain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO: 27 or 28.
[0401] Embodiment 21. An antibody or antigen-binding fragment thereof according to Embodiment 19 or 20, wherein the antibody or antigen-binding fragment thereof comprises a light chain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO: 33 or 34.
[0402] Embodiment 22. An antibody or antigen-binding fragment thereof comprising a heavy chain and a light chain, wherein the heavy chain has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity with SEQ ID NO: 27 or 28, and the light chain has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity with SEQ ID NO: 33 or 34.
[0403] Embodiment 23. A transgenic animal engineered to express the antibody or antigen-binding fragment thereof according to any one of Embodiments 19 to 22.
[0404] Embodiment 24. The transgenic animal of embodiment 23, wherein the animal is a rodent.
[0405] Embodiment 25. The transgenic animal of Embodiment 24, wherein the rodent is a mouse.
[0406] Embodiment 26. A nucleic acid encoding a heavy chain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO:27 or 28.
[0407] Embodiment 27. A nucleic acid encoding a light chain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO:33 or 34.
[0408] Embodiment 28. The antibody or antigen-binding fragment thereof according to any one of Embodiments 1 to 4, 10 to 13 or 19 to 22, wherein the antibody or antigen-binding fragment thereof is human, mouse, chimeric, humanized, monoclonal, bispecific, trispecific or multispecific.
[0409] Embodiment 29. An antibody or antigen-binding fragment thereof comprising three light chain CDRs having an amino acid sequence selected from the group consisting of SEQ ID NO: 12, 13, 14, 24, 25, 35, 36 or 37.
[0410] Embodiment 30. An antibody or antigen-binding fragment thereof comprising three heavy chain CDRs having an amino acid sequence selected from the group consisting of SEQ ID NO: 6, 7, 8, 18, 19, 20, 29, 30 or 31.
[0411] Embodiment 31. An antibody or an antigen-binding fragment thereof comprising three light chain CDRs and three heavy chain CDRs, wherein the three light chain CDRs have an amino acid sequence selected from the group consisting of SEQ ID NO: 12, 13, 14, 24, 25, 35, 36 or 37, and the three heavy chain CDRs have an amino acid sequence selected from the group consisting of SEQ ID NO: 6, 7, 8, 18, 19, 20, 29, 30 or 31.
[0412] Embodiment 32. An antibody or epitope-binding fragment or fusion protein thereof that immunospecifically binds to SEQ ID NO:38.
[0413] Embodiment 33. The antibody or epitope-binding fragment or fusion protein according to Embodiment 32, wherein the immune cell is a T cell.
[0414] Embodiment 34. The antibody or epitope-binding fragment or fusion protein according to Embodiment 33, wherein the T cell is a CD8+ T cell.
[0415] Embodiment 35. The antibody or epitope-binding fragment or fusion protein according to Embodiment 32, wherein the antibody or antigen-binding fragment or fusion protein binds to PD-1.
[0416] Embodiment 36. An antibody or an epitope-binding fragment or fusion protein thereof, which immunospecifically binds to SEQ ID NO: 38 on PD-1 expressed on the surface of immune cells and induces or promotes signals that activate or stimulate the immune cells through PD-1.
[0417] Embodiment 37. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of Embodiments 1 to 4, 10 to 13, 19 to 22 or 29 to 36.
[0418] Embodiment 38. The pharmaceutical composition of Embodiment 37, further comprising a second therapeutic agent.
[0419] Embodiment 39. The pharmaceutical composition according to embodiment 37 or 38, further comprising a pharmaceutically acceptable excipient.
[0420] Embodiment 40. The pharmaceutical composition of Embodiment 38, wherein the second therapeutic agent comprises cyclophosphamide.
[0421] Embodiment 41. A method of inducing, promoting or enhancing an immune response in a subject in need thereof, the method comprising:
[0422] An effective amount of the antibody or antigen-binding fragment of any one of embodiments 1 to 4, 10 to 13, 19 to 22 or 29 to 36, or the pharmaceutical composition of any one of embodiments 37 to 40 is administered to the subject to induce, promote or enhance an immune response in the subject.
[0423] Embodiment 42. A method for treating cancer in a subject in need thereof, the method comprising:
[0424] An effective amount of the antibody or antigen-binding fragment of any one of Embodiments 1 to 4, 10 to 13, 19 to 22, or 29 to 36, or the pharmaceutical composition of any one of Embodiments 37 to 40 is administered to the subject to treat cancer in the subject.
[0425] Embodiment 43. A method for reducing tumor burden in a subject in need thereof, the method comprising:
[0426] An effective amount of the antibody or antigen-binding fragment of any one of Embodiments 1 to 4, 10 to 13, 19 to 22, or 29 to 36, or the pharmaceutical composition of any one of Embodiments 37 to 40 is administered to the subject to reduce the tumor burden in the subject.
[0427] Embodiment 44. A method of treating an infection in a subject in need thereof, the method comprising:
[0428] An effective amount of the antibody or antigen-binding fragment of any one of Embodiments 1 to 4, 10 to 13, 19 to 22, or 29 to 36, or the pharmaceutical composition of any one of Embodiments 37 to 40 is administered to the subject to treat the infection in the subject.
[0429] Example
[0430] Example 1: Anti-PD-1 Antibody Production
[0431] result
[0432] Production of anti-PD-1 antibodies resulted in clones 4G9, 4C12, and 5C2 that were selected for characterization.
[0433] Example 2: Interaction kinetics between anti-PD-1 antibodies and PD-1
[0434] Materials and methods
[0435] Antibodies from clones 4G9, 4C12 and 5C2 were characterized using the Biocore™ system from GE. The analyte was mouse or human PD-1 and the ligand was an anti-PD-1 antibody. The indicated analyte concentrations were 0 nM, 62.5 nM, 125 nM, 250 nM, 500 nM and 1000 nM.
[0436] result
[0437] Figure 1 Table 1 shows the interaction analysis between 4G9 and human PD-1. The equilibrium association constant (KA) is 9.52×10 5 (1 / M). The equilibrium dissociation constant (KD) is 1.05×10 -6 (M).
[0438] Table 1. Interaction analysis of 4G9 and human PD-1.
[0439]
[0440] Figure 2 Table 2 shows the interaction analysis of 4G9 and mouse PD-1. The equilibrium association constant (KA) is 1.94×10 5 (1 / M). The equilibrium dissociation constant (KD) is 5.15×10 -6 (M).
[0441] Table 2. Interaction analysis of 4G9 and mouse PD-1.
[0442]
[0443] Figure 3 Table 3 shows the interaction analysis between 4C12 and human PD-1. The equilibrium association constant (KA) is 3.14×10 6 (1 / M). The equilibrium dissociation constant (KD) is 3.19×10 -7 (M).
[0444] Table 3. Interaction analysis of 4C12 and human PD-1.
[0445]
[0446] Figure 4 Table 4 shows the interaction analysis of 5C2 with human PD-1. Equilibrium association constant (K A ) is 2.02×10 5 (1 / M). Equilibrium dissociation constant (K D ) is 4.95×10 -6 (M).
[0447] Table 4. Interaction analysis of 5C2 and human PD-1.
[0448]
[0449] Figure 5 Table 5 shows the interaction analysis of 5C2 with mouse PD-1. Equilibrium association constant (K A ) is 1.18×10 6 (1 / M). Equilibrium dissociation constant (K D ) is 8.50×10 -7 (M).
[0450] Table 5. Interaction analysis of 5C2 and mouse PD-1.
[0451]
[0452]
[0453] Example 3: Binding of anti-PD-1 antibodies to EL4 cells
[0454] Materials and methods
[0455] Mouse EL4 cells constitutively expressing PD-1 were used in a fluorescence activated cell sorter to assess the binding of 4G9, 5C2, and 4C12 to the cells.
[0456] result
[0457] Fig. 6A is a flow cytometry histogram showing that commercial anti-PD-1 binds to EL4 cells while a control isotype antibody does not bind to EL4 cells. Figure 6B is a flow cytometry histogram showing binding of 4G9, 5C2, and 4C12 to EL4 cells, while the secondary antibody alone does not. Figure 6C is a flow cytometry histogram showing that 4G9 anti-PD-1 antibody binds to EL4 cells, while the secondary antibody alone does not. Fig.6D is a flow cytometry histogram showing that 5C2 anti-PD-1 antibody binds to EL4 cells, while the secondary antibody alone does not. Fig. 6E is a flow cytometry histogram showing that 4C12 anti-PD-1 antibody binds to EL4 cells, while the secondary antibody alone does not.
[0458] Example 4: Agonist activity of anti-PD-1 antibodies
[0459] Materials and methods
[0460] Mouse CD4 T cells
[0461] Purified mouse CD4 T cells were stimulated with anti-CD3 / anti-CD28 Ab for 48 h, and then anti-PD-1 Ab (10 μg / ml) was added to the culture together with protein A beads for another 48 h. In some samples, anti-PD-L1 Ab was added to block the PD-1 / PD-L1 interaction to dissect the agonist effect of the test Ab. IFNγ and IL-2 concentrations in the supernatant were measured using CBA assay.
[0462] Human CD4 T cells
[0463] Purified human CD4 T cells were stimulated with anti-CD3 / anti-CD28 Ab for 48 h, and then anti-PD-1 Ab (1 or 10 μg / ml) was added to the culture together with protein A beads for another 48 h. IFNγ concentrations in the supernatants were measured using a CBA assay.
[0464] result
[0465] Fig. 7A and Figure 7B showed that IFNγ and IL-2 concentrations were higher in the supernatants of stimulated CD4 T cells treated with anti-PD-1 antibodies 5C2, 4C12, and 4G9 compared with untreated cells or cells treated with anti-PD-L1 antibodies. Figure 7C showed that stimulated human CD4 T cells treated with the anti-PD-1 antibodies 4G9 and 5C2 had higher IFNγ supernatant concentrations compared with untreated cells or cells treated with an isotype control antibody.
[0466] Example 5: Hybridoma Enhances Akt Phosphorylation
[0467] Materials and methods
[0468] Intracellular staining of pAKT (S473) was used as a marker of T cell activation.
[0469] result
[0470] Hybridomas from mice immunized with peptide E enhanced phosphorylation of Akt(S473) in mouse CD4 T cells ( Figure 8 ).
[0471] Example 6: Characterization of three anti-PD-1 antibodies
[0472] Materials and methods
[0473] Purified antibodies from hybridomas 5C2, 4C12, and 4G9 were characterized.
[0474] result
[0475] The isotype of each of the three anti-PD-1 antibodies was determined. 5C2 and 4C12 were both IgG1 isotypes, and 4G9 was found to be IgG2b isotype ( Fig. 9 ). Hybridoma sequencing showed that the 5C2 and 4C12 antibodies had 100% sequence identity.
[0476] Example 7: 4G9 and 5C2 specifically bind to human PD-1
[0477] Materials and methods:
[0478] The binding of 4G9 and 5C2 to human PD-1-Fc was determined using an ELISA assay.
[0479] result:
[0480] Fig.10 The results of ELISA assays evaluating the binding of 4G9 and 5C2 antibodies to human PD-1-Fc are shown. Both 4G9 and 5C2 specifically bind to human PD-1. Fig.11A are flow cytometry histograms showing that 4G9 and 5C2 do not bind to PD-1KO CD4 T cells, but they do bind to CD4 T cells from wild-type mice ( Fig. 11B ).
[0481] Example 8: Signal transduction
[0482] Materials and methods:
[0483] Mouse CD4 T cells were pre-stimulated for 48 hours to ensure PD-1 expression and then treated with purified 4G9 and 5C2 antibodies. The concentration of pS6 was determined using an ELISA kit (Cell Signaling Tech).
[0484] result:
[0485] In contrast to blocking antibodies (RMP1-14 and J43), 4G9 and 5C2 activated T cells via the S6 pathway. Treatment of mouse CD4 T cells pre-stimulated for 48 h (to ensure PD-1 expression) with purified 4G9 and 5C2 antibodies resulted in a significant increase in pS6 within the linear range (ELISA kit Cell Signaling Tech, *P<0.05, **P<0.01, ***P<0.001 compared to untreated). This phenomenon was due to direct activation rather than PD-1 / PD-L1 blockade, as treatment with commercially available Ab-1 (RMP1-14) and Ab-2 (J43) that block PD-1 / PD-L1 interactions did not result in an increase in pS6.
[0486] Example 8: In vivo efficacy evaluation
[0487] Materials and methods:
[0488] Fig.13A is a schematic diagram of the TC-1 tumor model used in this experiment. Briefly, mice were injected subcutaneously with TC-1 tumor cells on day 0. Mice were treated with the vaccine (E7+PADRE+Quil A) on days 10 (D10), 17 (D17), and 24 (D24) after tumor injection. Mice were treated with anti-PD-1 antibodies on days 10, 14, 17, 21, 24, and 28.
[0489] result:
[0490] When used in combination with the E7 vaccine, the anti-PD-1 antibodies 4G9, 4C12, and 5C2 reduced tumor volume and improved survival ( FIG. 13B to FIG. 13D ).
[0491] Example 9: In vivo efficacy evaluation—anti-EpE antibodies
[0492] Materials and methods:
[0493] As in Example 8 and Fig.14A Antibodies against epitope E were generated and tested in the TC-1 tumor model as described in .
[0494] result:
[0495] Mice treated with 4G9, an antibody generated against epitope E, showed significantly lower tumor volume and higher survival rate compared with traditional checkpoint inhibitors, namely the anti-PD1 blocking antibodies RMP1-14 and J43 ( FIG. 14B to FIG. 14C ).
Claims
1. An antibody or antigen-binding fragment thereof comprising a heavy chain complementarity determining region (CDR) and a light chain CDR, wherein the heavy chain CDR has an amino acid sequence according to SEQ ID NOs: 6, 7 and 8, and the light chain CDR has an amino acid sequence according to SEQ ID NOs: 12, 13 and 14.
2. The antibody or antigen-binding fragment thereof of claim 1, comprising a heavy chain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO: 4 or 5.
3. The antibody or antigen-binding fragment thereof of claim 1 or 2, comprising a light chain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO: 10 or 11.
4. An antibody or any antigen-binding fragment thereof comprising a heavy chain and a light chain, wherein the heavy chain has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity with SEQ ID NO:4 or 5, and the light chain has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity with SEQ ID NO:10 or 11.
5. A transgenic animal engineered to express the antibody or antigen-binding fragment thereof according to any one of claims 1 to 4.
6. The transgenic animal of claim 5, wherein the animal is a rodent.
7. The transgenic animal of claim 6, wherein the rodent is a mouse.
8. A nucleic acid encoding a heavy chain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO:4 or 5.
9. A nucleic acid encoding a light chain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity to SEQ ID NO: 10 or 11.
10. An antibody or antigen-binding fragment thereof comprising a heavy chain CDR and a light chain CDR, wherein the heavy chain CDR has an amino acid sequence according to SEQ ID NOs: 18, 19 and 20, and the light chain CDR has an amino acid sequence according to SEQ ID NOs: 24, 13 and 25.
